Dida Inc. (02559.HK) Announced 2025 Annual Results, RMB 138 Million Adjusted Net Profit ACN Newswire

Dida Inc. (02559.HK) Announced 2025 Annual Results, RMB 138 Million Adjusted Net Profit

HONG KONG, March 24, 2026 - (ACN Newswire via SeaPRwire.com) – Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK), a leading technology-driven mobility platform, announced the audited consolidated annual results for the year ended December 31, 2025.Financial Highlights:- Revenue was RMB502.4 million for the year ended December 31, 2025, compared to RMB787.2 million for the year ended December 31, 2024.- Gross profit was RMB332.9 million for the year ended December 31, 2025, compared to RMB567.0 million for year ended December 31, 2024.- Net profit was RMB129.8 million for the year ended December 31, 2025, compared to RMB1,004.3 million for the year ended December 31, 2024.- Adjusted net profit (non-IFRS measure) was RMB137.9 million for the year ended December 31, 2025, compared to RMB221.4 million for the year ended December 31, 2025.Operation Highlights:- Gross transaction value amounted to RMB4.7 billion and the total number of orders reached 80.9 million for the year ended December 31, 2025.- Registered users reached over 415 million as of December 31, 2025.- The number of certified private car owners reached approximately 21 million as of December 31, 2025.Business OutlookMobility-related business 2025 marked a pivotal year as the Company transitioned from a single-focus carpooling platform toward a more integrated mobility and vehicle services platform. In 2025, the Company launched ride-hailing aggregation platform services to diversify service offerings. Such services are intended to complement the carpooling business by addressing additional mobility scenarios, including short-to-medium distance and immediate travel needs, in addition to the medium-to-long distance and pre-arranged travel scenarios typically served by carpooling. The Company also commenced used car trading referral services to expand business scope along the vehicle ownership lifecycle and enhance engagement within the Company’s car owner ecosystem. The Company believes carpooling in China is still at its early stage of development, with significant market demand yet to be fully released and the benefits of carpooling not fully recognized by the public. The Company will remain committed to innovation as the Company continues to develop unique competitive strengths and value around mobility scenarios to better serve the user base. In the future, the Company plans to further develop ride-hailing aggregation platform services and other mobility-related services and to continue to expand service offerings.For the full announcement of Dida for the annual results ended December 31, 2025, please visit:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf About Dida Inc.Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK) is a leading technology-driven mobility platform in China. The Company creates more transit capacity with less environmental impact by providing carpooling marketplace services to pair up riders with private car owners if they are heading in similar directions at compatible times. It also provides ride-hailing aggregation platform services to address additional mobility scenarios. Dida makes the mobility ecosystem greener and more efficient, and each trip experience warm and enjoyable.Forward-Looking StatementsThis press release contains forward-looking statements relating to the business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond the control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in the other public disclosure documents on the corporate website. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
嘀嗒出行(02559.HK)公布2025年全年业绩 经调整净利润达1.38亿元人民币 ACN Newswire

嘀嗒出行(02559.HK)公布2025年全年业绩 经调整净利润达1.38亿元人民币

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 中国领先的技术驱动移动出行平台嘀嗒出行(“嘀嗒”或“公司”,股票代码:02559.HK)公布了截至2025年12月31日止年度的经审计综合年度业绩。财务亮点:-截至2025年12月31日止年度,收入为人民币5.02亿元,2024年同期为7.87亿元。-截至2025年12月31日止年度,毛利为人民币3.33亿元,2024年同期为5.67亿元。-截至2025年12月31日止年度,净利润为人民币1.30亿元,2024年同期为10.04亿元。-截至2025年12月31日止年度,经调整净利润(非国际财务报告准则计量)为人民币1.38亿元,而2024年同期为2.21亿元。运营亮点:-截至2025年12月31日止年度,交易总额达人民币47亿元,订单总数达到8090万。-截至2025年12月31日,注册用户数超过4.15亿。-截至2025年12月31日,认证私家车主数量达到约2100万。业务展望:出行相关业务2025年是嘀嗒出行从专注于顺风车的平台,向更为综合的出行及车辆服务平台转型的关键之年。2025年,嘀嗒出行推出了聚合打车业务,来进一步丰富平台的出行场景,使“中短途+立即出发“的即时出行需求与顺风车”中长途+预约出行“的场景形成有效互补,增强用户在不同出行决策场景下的选择弹性。嘀嗒出行还开启了二手车交易线索业务,拓展车辆全生命周期的业务范围,并提升车主生态的用户参与度。嘀嗒出行认为,顺风车在中国仍处于早期发展阶段,有潜在的巨大市场需求还未被充分释放,而顺风车的益处还未被完全认知。嘀嗒出行将持续致力于创新,围绕平台的出行场景,继续发展平台独特的竞争优势和价值,以更好地服务用户群体。未来,嘀嗒出行计划进一步发展聚合打车业务及其他出行相关服务,并持续扩展服务品类。有关嘀嗒出行截至2025年12月31日止年度全年业绩公告的完整内容,请访问:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf关于嘀嗒出行嘀嗒出行("嘀嗒"或"公司",股票代码:02559.HK)是中国领先的技术驱动型出行平台。公司通过提供顺风车平台服务,为乘客和出行路线及时间相近的私家车主进行匹配,从而在不增加环境负担的前提下创造了更多运力。公司还提供聚合打车服务,以满足更多元的出行场景需求。嘀嗒出行致力于让出行生态更绿色、更高效,让每一次出行体验温暖而愉悦。前瞻性声明本新闻稿包含有关公司业务前景、预测业务计划和增长战略的前瞻性陈述。这些前瞻性陈述基于公司目前信息,并基于本新闻稿发布时的前景进行陈述。它们基于某些期望、假设和前提,其中一些是主观的或不可控的,可能被证明是不正确的,未来可能无法实现。前瞻性陈述背后存在大量风险和不确定性。有关这些风险和不确定性的更多信息,请参阅公司网站上的其他公开披露文件。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY ACN Newswire

TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - On March 23, 2026, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its 2025 annual results. In 2025, amid drastic changes in consumer behaviours and a complex market environment, the Group remained firmly committed to the consumer-centric approach, advanced the high-quality development in a coordinated manner, promoted product innovation and upgrades to precisely meet the demands of diverse scenario-based needs, while accelerating the expansion into high-growth channels. It comprehensively improved overall operational efficiency and drove steady growth of all key financial indicators. For the twelve months ended on December 31, the Group’s revenue decreased by 2.0% year-on-year to RMB 79.068 billion. Among which, the revenue from the Instant Noodles Business was RMB28.421 billion, while the revenue from the Beverages Business was RMB50.123 billion. The gross profit margin grew 1.7 percentage points to 34.8% year-on-year, EBITDA increased by 10.2% year-on-year to RMB 10.607 billion. The profit attributable to shareholders of the Company increased significantly by 20.5% year-on-year to RMB4.501 billion. The directors recommended the payment of a final dividend and a special final dividend of RMB39.92 cents and RMB39.92 cents per ordinary share respectively. Dividend payout ratio for the year remained at 100%.Financial Summary For the twelve months ended 31 December RMB’00020252024ChangeRevenue79,068,02280,650,914↓ 2.0%Gross margin34.8%33.1%↑ 1.7ppt.Gross profit of the Group27,531,70426,695,643↑ 3.1%EBITDA10,606,5229,627,802↑ 10.2%Profit for the period5,175,8524,322,135↑ 19.8%Profit attributable to owners of the Company4,500,6983,734,429↑ 20.5%Earnings per share (RMB cents) Basic79.8666.28↑ 13.58 centsDiluted79.8466.28↑ 13.56 centsAs at 31 December 2025, cash at bank and on hand (including long-term time deposits) was RMB19,486.056 million, representing an increase of RMB3,483.388 million when compared to 31 December 2024. Gearing ratio was -29.8%.In 2025, China's economy demonstrated resilience with a 5% year-on-year GDP growth. However, the food and beverage market entered into the stage of stock competition and demand upgrading for functional and emotional values. Brand, quality, and flavors remained key drivers of purchasing decisions. Additionally, emerging formats such as instant retail, snack discount stores, and membership stores had brought about drastic changes in channels and consumer behaviors. Against the backdrop of intensifying market competition and evolving consumption patterns, a company's core competitiveness increasingly lies in building a strong moat for their core brands. Those that continuously drive product innovation and channel optimization around consumer needs will be more agile in capturing market opportunities, strengthening consumer trust, and ultimately achieving high-quality and sustainable long-term development.In 2025, the gross profit of the Instant Noodles business improved steadily. The Group’s revenue from the Instant Noodles Business was RMB28.421 billion, which grew slightly year-on-year, accounting for 35.9% of the Group’s total revenue. During the year, due to favorable raw material prices and selling prices, the gross profit margin of instant noodles expanded by 1.1 percentage points year-on-year to 29.7%, and the profit attributable to shareholders of the Company for the year of 2025 in the Instant Noodles Business increased significantly by 10.1% year-on-year to RMB 2.252 billion, driven by the year-on-year increase in gross profit margin. During the year, in the face of intensifying industry competition, the Instant Noodles Business steadily advanced its core strategy of “consolidating blockbuster products, seizing the popular flavors track, and cultivating innovative products.” By continuously improving the product portfolio and forging deep collaborations with popular IPs, it effectively amplified brand presence and steadily optimized gross margin structure. On the product front, the business relied on deep cultivation of core blockbuster products and iterative flavor upgrades, while closely aligning with evolving consumer trends to precisely target the health-focused and premium market segments, tapping into new growth opportunities. On the marketing front, it leveraged mainstream social platforms such as Bilibili and Xiaohongshu to conduct omnichannel communication, combined with cross-industry collaborations with well-known IPs to reinforce the brand perception of high-end and convenient consumption. As a result, brand influence and market recognition improved significantly. Meanwhile, guided by aerospace-grade quality standards, the business promoted the full application of aerospace patented temperature control technology in the production line, fully demonstrating the brand’s differentiated advantages in product quality and technological innovation.The Beverages Business firmly executed the strategy of “consolidating core products and developing innovative products”, the revenue from the Beverages Business was RMB50.123 billion, accounting for 63.4% of the Group’s total revenue. During the year, due to favorable raw material prices and optimized product mix, the gross profit margin of Beverages expanded by 2.2 percentage points year on-year to 37.5%. Driven by a year-on-year expansion of gross profit margin, the profit attributable to shareholders of the Company in the Beverages Business for the year of 2025 increased significantly by 18.5% year-on-year to RMB 2.274 billion. During the year, the Beverages Business strengthened its core category advantages and proactively positioned itself in emerging tracks, establishing a collaborative growth model across the full product portfolio. On the product front, while consolidating core products, it continuously expanded into incremental growth segments by launching high-quality sugar-free offerings and aligning with the wellness consumption trend to create herbal wellness scenarios, successfully opening up new growth spaces such as products made from homologous medicinal and food materials. On the marketing front, the Company deepened IP collaborations to broaden audience reach, enhanced its presence in cultural tourism channels and high-end hotel partnerships, and targeted premium consumption scenarios. These efforts consistently elevated brand value, providing strong support for the business to achieve steady operations and sustainable growth.Mr. Wei Hong-Chen, Chief Executive Officer, commented, “As the first year of the 15th Five-Year Plan period, 2026 is expected to see expanding domestic demand become a key driver of economic growth under a more proactive and effective macroeconomic policy, while the consumer market will also usher in a critical window of profound transformation. The food and beverage industry will closely follow the theme of high-quality development, and consumption stratification will become more refined. Functional attributes, emotional resonance, and green concepts are shifting from trends to mainstream factors, becoming core elements driving brand growth. In the face of opportunities and challenges in the new cycle, the Group will be guided by the spirit of “Back to Day 1” as its strategic direction, embracing the efficiency, agility and entrepreneurial drive of our founding days, and building a platform that encourages honesty, bold experimentation and mutual growth, thus fully unleashing the vitality of all employees. While unleashing organizational vitality, we will continue to strengthen our foundational R&D capabilities and digital operation systems. Rooted in the health needs of the nation, we will drive product iteration and upgrades through technological innovation, continuously elevate product value, and align high-quality supply with the evolving consumption landscape. Adhering to the “economic-ESG” sustainable development philosophy, we will internalize social responsibility as the foundation of our development, solidify user trust through quality products, build a brand moat with long-term value, and create a sustainable and stable return system for shareholders, propelling the Group toward steady and sustained progress in the new stage of high-quality development.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the “PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.For enquiries, please contact:Investor EnquiriesInvestor Relations Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedStephanie ChenE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
康师傅控股有限公司2025年业务持续向好 凝心聚力再启新程 ACN Newswire

康师傅控股有限公司2025年业务持续向好 凝心聚力再启新程

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 2026年3月23日,康师傅控股有限公司(0322.HK,以下简称"公司",连同其附属公司"集团")发布2025年年度业绩公告。2025年,在消费行为剧烈变革与市场环境复杂多变的背景下,本集团始终坚持以消费者为中心,统筹推进高质量发展,推动产品创新升级,精准满足多元场景需求,同时加速开拓高增长渠道,全面提升整体运营效能,推动各项财务指标稳健发展。截至2025年12月31日止十二个月,集团收益同比衰退2.0%至790.68亿人民币。其中,方便面事业收益284.21亿人民币,饮品事业收益为501.23亿人民币。毛利率同比提高1.7个百分点至34.8%,EBITDA同比增长10.2%至106.07亿人民币,本公司股东应占溢利同比成长20.5%至45.01亿人民币。董事会建议派发末期股息每股普通股人民币39.92分及特别末期股息每股普通股人民币39.92分,全年派息率达100%。财务摘要 截至12月31日止12个月 人民币千元2025年2024年变动收益79,068,02280,650,914↓ 2.0%毛利率(%)34.8%33.1%↑ 1.7个百分点集团毛利27,531,70426,695,643↑ 3.1%扣除利息、税项、折旧及摊销前盈利(EBITDA)10,606,5229,627,802↑ 10.2%本期溢利5,175,8524,322,135↑ 19.8%本公司股东应占溢利4,500,6983,734,429↑ 20.5%每股溢利(人民币分) 基本79.8666.28↑ 13.58分摊薄79.8466.28↑ 13.56分于2025年12月31日之银行存款及现金(含长期定期存款)为人民币19,486,056千元,相较2024年12月31日增加人民币3,483,388千元,净负债与资本比率为-29.8%。2025年,中国经济在GDP同比5%的增长中展现韧性。但食品饮料市场进入存量博弈,以及对功能价值与情绪价值需求升级阶段。品牌、品质与风味仍是购买决策的重要驱动因素。此外,即时零售、零食折扣店、会员店等新兴业态带来渠道与消费行为剧烈变革。在市场竞争日趋激烈、消费行为持续演变的背景下,企业的核心竞争力愈发体现在核心品牌的护城河建设。能够围绕消费者需求,持续推动产品创新与渠道优化的企业,将更敏捷地捕捉市场机遇,巩固消费者信任,进而实现高质量、可持续的长远发展。2025年,方便面事业的毛利结构持续改善。方便面事业收益为284.21亿人民币,同比微幅增长,占集团总收益35.9%。年内,因原材料价格及售价有利,使方便面毛利率同比提高1.1个百分点至29.7%,由于毛利率同比提高带动,令方便面事业2025年全年的本公司股东应占溢利同比大幅增长10.1%至22.52亿人民币。年内,面对日趋激烈的行业竞争,方便面业务扎实推进"巩固大单品、占领大口味赛道、培育创新产品"的核心战略,通过持续完善产品矩阵,与热门IP深度联动,有效放大品牌声量,稳步优化毛利结构。产品端,依托核心大单品深耕与口味迭代升级,同时紧密贴合消费趋势变化,精准布局健康化、高端化赛道,精准切入新增量市场。营销端,依托B站、小红书等主流社交平台开展全域传播,叠加知名IP跨界合作,深化高端便捷的品牌认知,品牌影响力与市场认知度显著提升。同时,以航天品质为引领,推动航天专利温控技术在生产线全面落地应用,充分彰显品牌在产品品质与科技含量的差异化优势。饮品事业坚定实施"巩固核心单品、发展创新产品"战略。饮品事业整体收益为501.23亿人民币,占集团总收益63.4%。年内,因原材料价格有利及产品组合优化,使饮品毛利率同比提高2.2个百分点至37.5%。由于毛利率同比提高带动,令饮品事业2025年全年本公司股东应占溢利同比大幅提高18.5%至22.74亿人民币。年内,饮品事业通过深化核心品类优势与前瞻性布局新兴赛道,构建全品类协同增长格局。产品端,在稳固核心单品的基础上,持续拓展增量赛道,推出高品质无糖产品,并紧扣养生消费趋势,打造草本养生场景,成功开辟药食同源等新增量空间。营销端则持续强化IP深度合作拓宽受众圈层,同时强化文旅渠道布局及高端酒店合作,锚定高端消费场景,持续提升品牌价值,为业务实现稳健经营与可持续增长提供有力支撑。康师傅首席执行官魏宏丞先生表示:"2026年作为"十五五"开局之年,预计在更加积极有为的宏观政策下,扩大内需将成为经济增长的关键着力点,消费市场也将随之迎来深度变革的关键窗口。食品饮料行业围绕高质量发展主线持续演进,消费分层愈加精细,功能价值、情绪共鸣与绿色理念正从趋势走向主流,成为驱动品牌增长的核心要素。面对新周期中的机遇与挑战,集团将以"Back to Day 1"的精神为战略引领,回归创业初期的高效敏捷与狼性拼搏文化,打造敢讲真话、勇于尝试、共同成长的平台,充分激发全员活力。在释放组织活力的同时,我们将持续夯实基础研发能力与数字化运营体系,立足国民健康诉求,以科技创新驱动产品迭代升级,推动产品价值不断跃迁,以高品质供给适配新消费结构。秉持"economic-ESG"可持续发展理念,我们将社会责任内化为发展底色,通过优质产品夯实用户信赖,以长期价值构建品牌护城河,为股东打造可持续的稳健回报体系,推动集团在高质量发展新阶段行稳致远。"关于康师傅控股有限公司(0322.HK)康师傅控股有限公司("本公司")及其附属公司("本集团")主要在中国从事生产和销售方便面及饮品。本集团于1992年开始生产方便面,并自1996年起扩大事业至方便食品及饮品;2012年3月,本集团进一步拓展饮料事业范围,完成与PepsiCo中国饮料事业之战略联盟,开始独家负责制造、灌装、包装、销售及分销PepsiCo于中国的非酒精饮料。"康师傅"作为中国家喻户晓的品牌,经过多年的耕耘与积累,深受中国消费者喜爱和支持。如有垂询,请联络:投资者查询康师傅控股有限公司投资者关系团队电邮:ir@tingyi.com汇思讯中国有限公司陈敏芝电邮:stephanie.chen@christensencomms.com电话:+852 2117 0861 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
全景业务布局+AI双轮驱动 麦迪卫康业绩扭亏为盈打开广阔成长空间 ACN Newswire

全景业务布局+AI双轮驱动 麦迪卫康业绩扭亏为盈打开广阔成长空间

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 3月23日,麦迪卫康正式发布2025年度业绩公告。 数据显示,公司年内溢利约人民币698万元,盈利能力显著修复,全年扭亏为盈,经营性现金流状况持续好转。 业绩改善主要得益于“AI+数字化”带动核心主营业务持续稳健增长,叠加公司聚焦高毛利优质项目,有效带动整体毛利水平显著提升。此次公司财务表现展现出强劲的修复弹性,是公司发展历程中的重要里程碑。 一方面,标志着公司聚焦主业、优化业务结构的战略取得实质性成效,经营质量与盈利能力迈入全新阶段,为后续稳健发展筑牢财务根基; 另一方面,充分印证公司核心业务具备强劲增长韧性与市场竞争力,高毛利项目布局持续释放效益,也为公司深化医疗健康服务布局、拓展优质业务版图注入更强信心,进一步巩固行业竞争力与可持续发展能力。3C服务体系覆盖全产业链 技术创新构筑核心竞争力经营效率的跨越式进步,离不开公司清晰的业务布局与精准的战略定位。 在业务布局方面,麦迪卫康以创新数字医疗服务提供商为定位,打造独具竞争力的「3C服务体系」,涵盖专业医学内容服务(Content)、高端学术会议服务(Conference)、企业市场推广服务(Corporation)三大核心领域,形成了覆盖医疗全产业链的服务闭环,为业务高质量发展筑牢根基。2025年,公司数字化医学平台的运营步入高质量发展的新阶段。 该平台不仅实现了专业医疗群体的高密度覆盖,更在海量的学术交流与卫教传播中,构筑起一套精准、专业且具备高度粘性的知识服务体系。 这种深度的数字化转型,不仅显著提升了医学内容的传播效能与学术影响力,更在赋能医生临床决策、助力健康知识普及方面发挥了关键作用,转化为推动行业进步的实质性力量,进一步巩固了公司在数字医疗生态中的引领地位。持续的技术创新,是驱动麦迪卫康高质量增长的核心引擎。 在技术研发领域,公司拥有多项软件著作权与发明专利,自主研发的长颈鹿系列数智平台已吸引数十万名医生入驻,显著提升医疗服务与运营管理效率。 2024年,公司持续深化AIGC场景落地,创新推出「AI智能体+医生众创」模式,助力医生回归高价值诊疗与科研工作; 同时依托区块链技术成功获得数据服务商资质,实现医学内容确权与授权运营,为医疗数字化生态建设树立行业标杆。2025年,公司深入推进AI智能体的研发与场景应用探索,致力于与医疗专业人士协同,打造「AI+人工」深度融合的医学内容数据标注及版权内容生产体系,并与数字资产交易平台业务形成有机衔接。 此外,依托专病管理AI智能体所取得的阶段性突破,公司正进一步将数智化能力向产业上下游延伸,前瞻性地探索智能专病机器人赛道; 同时,通过对柏慧康生物的战略投资,公司正积极探索在多组学创新检测领域的落地应用并已取得阶段性进展,借此构建起立体化的医疗创新服务网络。全国服务网络纵深覆盖 打开长期价值成长空间依托成熟的业务体系与核心技术支撑,麦迪卫康已搭建起覆盖全国的专业服务网络。 目前,公司在全国设立近10家经营机构,重点布局北京、上海、南京等核心医疗枢纽城市,服务合作三级医疗机构超3000家,其中包括北京天坛医院、阜外医院等国内顶尖三甲医院。同时,公司深度参与卒中中心、胸痛中心等重点专科建设,构建起纵向贯通、横向协同的全域专科医疗服务体系,为业务高效落地与市场持续拓展提供了坚实保障。广泛覆盖的服务网络与专业高效的服务能力,让麦迪卫康积累起优质且多元的客户群体,行业龙头地位持续巩固。 在数字医疗领域,公司自有互联网医疗平台已汇聚注册医生超5万名、注册患者近36万人次,2025年线上咨询量突破50万次,同比增长超19%,实现优质医疗资源高效触达,有效缓解医疗资源分配不均难题。从行业发展趋势来看,在人口老龄化加剧、慢性病管理需求攀升、政策持续赋能及AI数字技术深度渗透等多重驱动下,中国数字医疗产业正迎来黄金发展期,据中商产业研究院数据预测,2025年中国数字医疗市场规模预计达5800亿元, 2031年突破1.2万亿元,广阔的市场增量为麦迪卫康这类具备核心技术壁垒与全链条布局的领军企业,提供了持续成长与价值释放空间。麦迪卫康以「3C服务体系」为基座,以技术创新与服务升级为引擎,凭借覆盖全国的服务网络、广泛优质的客户资源以及前瞻性的战略布局,在行业内构建了独特的竞争优势与地位。 未来,随着数字医疗产业的持续升温与公司业务的不断深化,公司将紧抓医疗智能化转型的时代机遇,聚焦AI小模型赋能,全面拓展业务版图,夯实「AI+区块链」技术底座,探索搭建全流程智能闭环体系。 同时以「医学专业服务+数字化技术」双轮驱动,持续拓宽业务边界、优化内部运营效能,在数字医疗赛道上实现更高质量的发展,打开广阔成长空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study ACN Newswire

International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study

Sydney, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - The International Career Institute (ICI) is marking its 20th anniversary with the launch of 100 scholarships, in a milestone initiative designed to widen access to flexible, career-focused online study. The scholarship announcement comes as more students look for practical ways to upskill, change careers or strengthen their professional credentials without putting work or family life on hold.New scholarships launched as International Career Institute celebrates two decades of career-focused educationTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_001full.jpgOver the past two decades, the International Career Institute has built its reputation as an independent private provider of online education focused on practical, job-relevant learning. ICI offers 57 courses, has supported 58,453 students, and has learners in 191 countries, reflecting a substantial international footprint.The anniversary scholarship campaign is intended to do more than mark a birthday. It reflects a wider shift in the education market, where students are increasingly prioritising flexibility, affordability and direct career outcomes. ICI positions itself around exactly those needs: online delivery, self-paced study, personal tutor support, included course materials, flexible payment plans and career services aimed at helping graduates move into employment or advance in their chosen field.Applicants for the Leadership Scholarships are asked to demonstrate leadership potential or current leadership responsibilities and to complete an application process that outlines their background and motivation for study. Applicants facing financial disadvantage will be given priority. The scholarship forms part of a broader ICI scholarship offering and positions the initiative as a way to recognise leadership and help recipients take the next step in their development.For many adult learners, flexibility is not simply an added benefit; it is the condition that makes study possible. At the International Career Institute, students can study at their own pace, with no classes to attend and no additional textbooks or materials to purchase. Its online study model is structured around module-based written assessments rather than traditional exams, while students receive guidance and feedback from personal tutors throughout the course.Dr Michael Machica, Director of the International Career Institute, said the anniversary was both a celebration of the institution's history and a statement of intent for its future."Reaching 20 years is a proud milestone for the International Career Institute and a moment to reflect on how education has changed. From the beginning, our goal has been to make career-focused learning more flexible, more practical and more accessible for people whose lives do not fit the traditional study model. Over the next 20 years, we see ICI continuing to expand its reach, strengthen its industry relevance and help even more learners build meaningful careers through online education that works in the real world."That long-term focus on accessibility and employability remains central to the International Career Institute brand. Central to ICI's offering is tutor support, affordable pricing, interest-free payment plans, included materials and graduate career services. Those services include assistance with resumes, job searches, cover letters and interview preparation - features that help distinguish ICI in a competitive online learning market where students are increasingly outcome-focused.ICI's programmes are developed in consultation with industry experts and aligned with real-world job opportunities. That proposition - flexible study paired with career relevance - has become increasingly important as more learners seek education that fits around existing work, business, or family commitments while still contributing to employability and advancement.The release of 100 scholarships also gives the anniversary a broader public-interest dimension. In a cost-conscious environment, even motivated learners can hesitate when considering professional study. By offering scholarships focused on leadership and development, ICI is positioning its 20th anniversary not simply as a milestone but as an opportunity to invest in the next generation of professionals and career changers.Prospective students can explore scholarship eligibility, course options and the International Career Institute online study model through the institute's website, where they can also view course pages, student reviews and information about graduate support. For those considering a career change, promotion pathway or a more flexible way to formalise their skills, the anniversary scholarships create a timely reason to act.About International Career InstituteICI is an independent private provider of online education and training established in 2006. It offers career- and lifestyle-focused courses through a fully online, self-paced study model supported by personal tutors and graduate career services.Media ContactFor media enquiries, please contact:Email: info@ici.net.au Website: www.ici.net.auInternational Career InstituteTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_002full.jpgTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/288837 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion ACN Newswire

Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") provides clarification to its news release dated March 2, 2026, announcing the Preliminary Economic Assessment ("PEA") for the Company's 100% owned Hat Project in northwestern British Columbia.Following publication of the March 2, 2026 news release, Mineit Consulting Inc., the independent engineering firm responsible for the PEA, completed a further review of the application of certain processing cost assumptions relating to the scandium recovery circuit in Scenario B. As a result of this review, the after-tax NPV(5%) for Scenario B at consensus metal prices has been updated to C$7.27 billion from C$6.94 billion and IRR of 19%. The update also results in an increase in Scenario B after-tax NPV(5%) at spot metal prices to C$14.85 billion from C$14.52 billion and IRR of 32%.The updated Scenario B results further demonstrate the economic contribution of the scandium recovery circuit and increase the difference in after-tax NPV between the base case (Scenario A2) and Scenario B to C$547 million.The cobalt grade reported in Table 1 of the Company's March 2, 2026 news release was inadvertently shown as 0.78 g/t Co. The correct value is 78 g/t Co, consistent with Table 5 of the release. This discrepancy was limited to the summary table presentation and does not affect the PEA results or conclusions.These clarifications do not change the overall conclusions of the PEA and further highlight the strong economics of the Hat Project, including the potential value contribution from scandium recovery.Corrected highlights of the PEA reflecting the updated Scenario B economics are presented below.NPV:After-tax NPV(5%) of C$6.73 billion and IRR of 23% at Consensus Metal Prices After-tax NPV(5%) of C$13.53 billion and IRR of 39% at Spot Metal PricesNPV Including scandium and the associated processing circuit: After-tax NPV(5%) of C$7.27 billion and IRR of 19% at Consensus Metal PricesAfter-tax NPV(5%) of C$14.85 billion and IRR of 32% at Spot Metal PricesThree processing scenarios were evaluated-Scenario A1 (A1) a Cu-Au-Ag-Co flotation base case using current testwork recoveries1, Scenario A2 (A2), the same base case using expected recoveries1, and Scenario B (B), a Cu-Au-Ag-Co flowsheet with an added hydrometallurgical circuit and scandium recovery circuit, with results indicating the Project is financially attractive even without the scandium component.Highlights:Robust Project Economics: The PEA demonstrates a high-margin operation with an After-Tax NPV(5%) of C$4.96 billion (A1), C$6.73 billion (A2), or C$7.27 billion (B), and an IRR of 19% (A1), 23% (A2), or 19% (B) at analyst consensus metal prices2. Using a spot-price scenario3, the Project delivers a compelling after-tax NPV(5%) of C$11.05 billion (A1), 13.53 billion (A2), or C$14.85 billion (B) and an IRR of 34% (A1), 39% (A2), or 32% (B).Sensitivity Highlight: Project economics show the greatest leverage to overall metal prices, with NPV (5%) ranging from C$3.2 billion to C$10.2 billion (IRR: 14%-32%) at ±20% on all metals; even under additional +20% CAPEX and +20% OPEX sensitivities, applied on top of a 25% contingency already embedded in the base case, all scenarios deliver IRRs of 16% or better, and Scenario B provides additional scandium oxide upside with NPV(5%) of C$6.5 billion-C$8.1 billion (IRR: 18%-20%) at ±40% metal price.Scale and Longevity: The mine plan supports a multi-decade life of 25 years at a 120,000 tonnes-per-day processing rate, underpinned by a resource base of 609 Mt at 0.43% CuEq4 in the Measured and Indicated categories and 503 Mt at 0.41% CuEq4 in the Inferred category.High-Output Production Profile B: Envisioned as a conventional large-scale open-pit operation, the Project is expected to produce an average of over 74 kt of copper, 254 koz of gold, 376 koz of silver and 2.7 kt of cobalt annually during the first 10 years, with life-of-mine (LOM) average production of 67.6 kt Cu, 217 koz Au, 348 koz Ag, 2.5 kt Co, and 128 tonnes of scandium oxide per year. (NOTE: based on publicly reported 2024 North American cobalt mine production of approximately 3,800-4,000 tonnes (Natural Resources Canada; U.S. Geological Survey), the projected cobalt output is estimated to represent approximately 69% of current regional mined supply).Strategic Importance for Critical Minerals: The Project is positioned as a primary North American source of copper, scandium, and cobalt. With approximately 2.42 billion pounds of copper, 80 million pounds of cobalt and 2,415 tonnes of scandium oxide contained5 in the Measured and Indicated categories, the Project represents an important discovery of critical minerals.Stable, Supportive Jurisdiction: Located in a premier mining district in British Columbia, the Project benefits from a stable regulatory environment. The Company is committed to engaging with local First Nations in a respectful manner and to working toward positive and constructive relationships as the Project advances.Catalyst for Development: The PEA serves as the technical foundation for an immediate transition into a Pre-Feasibility Study (PFS), providing a clear roadmap for early works and permitting activities in 2026 and 2027.Farshad Shirvani, President and CEO of Doubleview Gold Corp., commented, "The results of this PEA confirm the scale, strength and long-term potential of the Hat Project. Delivering a post-tax NPV(5%) of up to C$6.73 billion and IRR of up to 23% at consensus prices, and even stronger metrics at spot prices, validates years of disciplined exploration and technical work by our team. Hat is demonstrating Tier 1 characteristics with a 25-year mine life, strong annual production profile and meaningful free cash flow generation. Importantly, the Project stands on its own without reliance on scandium, while still preserving significant upside from critical minerals as markets mature. We are excited to advance Hat to Pre-Feasibility and continue building a major Canadian critical metals project."Doubleview acknowledges that the Project is located on the traditional territories of the Tahltan Nation and the Taku River Tlingit First Nation, and recognizes their enduring relationship to and stewardship of the land and waters. Doubleview is committed to respectful, transparent, and ongoing engagement with First Nations and local communities whose territories overlap the Project area and access routes, with a focus on protecting water and the environment and advancing responsible development.PEA OVERVIEWThe PEA contemplates a conventional open-pit mine and processing operation with a 25-year mine life at a 120,000 t/d (42 Mt/a) plant throughput. Two processing pathways were evaluated, A1 and its alternative, A2, and B: the first alternative, A, is a Cu-Au-Ag-Co flotation concentrator with two recovery cases based on current metallurgical testwork, and A2, reflecting expected performance (Figure 1); and B, a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit (Figure 2).The tailings storage facility is a centreline-raised facility built with compacted cycloned sand from tailings underflow, and engineered drainage for stability, with site-contact waters (including seepage and pit dewatering) recycled to the process plant and final closure involving pond drainage and reclamation. The Project is expected to rely on grid power via an extended transmission line.Tables 1 to 3 summarize the key results of the PEA, including production, operating costs, capital expenditures, and the principal financial metrics; the sections that follow provide additional detail on the underlying assumptions, project design, and study outcomes.Table 1: PEA Study Summary-ProductionMetric UnitScenario A1Scenario A2Scenario BMining SummaryStrip ratiot:t1.60Production Summary LOMAverage Annual ThroughputMt42CuEq Head Grade6, 7%0.42Cu Head Grade%0.19Au Head Gradeg/t0.19Ag Head Gradeg/t0.51Co Head Gradeg/t77.73Sc Head Grade6g/t28.35Cu Recovery%8089858Au Recovery%6675898Ag Recovery%5353688Co Recovery%3030788Sc Recovery%N/A728Overall Mass of Tailings to Process9%N/A12.5Year of Production Start of Sc2O38yearN/A4Average Annual Cu Productionkt63.670.867.6Total Cu Productionkt1,590.51,769.41,689.9Average Annual Payable Cukt61.768.765.7Total Payable Cukt1,542.81,716.31,642.2Average Annual Au Productionkoz161.1183.1217.3Total Au Productionkoz4,028.24,577.55,432.0Average Annual Payable Aukoz153.1173.9207.5Total Payable Aukoz3,826.84,348.75,188.6Average Annual Ag Productionkoz271.3271.3348.0Total Ag Productionkoz6781.66,781.68,700.9Average Annual Payable Agkoz244.1244.1318.6Total Payable Agkoz6,103.46,103.47,965.3Average Annual Co Productionkt1.01.02.5Total Co Productionkt23.923.962.2Average Annual Payable Cokt0.80.82.3Total Payable Cokt19.119.156.3Average Annual Sc2O3 ProductiontN/A128.4Total Sc2O3 ProductiontN/A3,209.5Total Sc2O3 PayabletN/A3,049.0 Table 2: PEA Study Summary-Operating CostMetricUnitScenario A1Scenario A2Scenario BOperating Cost Average Mine Operating CostsC$/t-moved2.32Average Mine Operating CostsC$/t-milled6.03Processing Operating Cost10C$/t-milled7.937.9310.84Sc2O3 Processing Cost11C$/kg Sc2O3N/A939.55General & AdministrativeC$/t-milled2.562.562.56Total Operating CostsC$/t-milled16.2216.2221.92 Table 3: PEA Study Summary-Capital Expenditure and Financial MetricsMetricUnitScenario A1Scenario A2Scenario BCapital Expenditure Initial Capital CostsC$M3,5523,6013,828Sustaining Capital CostsC$M2,7552,7554,006Closure and Reclamation CostC$M503Financial Metrics Exchange RateCAD/USD1.37Long Term Copper PriceUS$/lb4.88Long Term Gold PriceUS$/oz3,272.60Long Term Silver PriceUS$/oz50.22Long Term Cobalt PriceUS$/lb19.57Long Term Scandium Oxide PriceUS$/kgN/A1,500Average Annual EBITDAC$M8861,0711,284Total EBITDAC$M22,16226,77032,101Average Annual Free Cash Flow (Pre-tax)C$M7569401,104Free Cash Flow (Pre-tax)12C$M18,90423,51127,592Total Provincial Tax (inc. BC Mineral Tax)C$M(4,029)(5,090)(6,019)Total Federal TaxC$M(1,274)(1,859)(2,308)Total TaxesC$M(5,303)(6,949)(8,327)Average Annual Free Cash Flow (Post-tax)C$M544662771Free Cash Flow (Post-tax)12C$M13,60116,56219,265Total Free Cash Flow (Pre-tax)13C$M15,35219,91023,764Total Free Cash Flow (Post-tax)12C$M10,05012,96115,437NPV 5% (Pre-tax)C$M7,88310,57611,567NPV 5% (Pre-tax)US$M5,7547,7208,443IRR (Pre-tax)%242923Payback (Pre-tax)yearsYear 5Year 4Year 6NPV 5% (Post-tax)C$M4,9636,7277,274NPV 5% (Post-tax)US$M3,6234,9115,309IRR (Post-tax)%192319Payback (Post-tax)YearsYear 6Year 5Year 7 Table 4 shows the Sensitivity analysis using after-tax NPV(5%) and after-tax IRR.Table 4: Sensitivity AnalysisVariableCase(%)Metal PriceScenario A1Scenario A2Scenario BNPV (5%) C$MIRR(%)NPV (5%)C$MIRR(%)NPV (5%)C$MIRR(%)Base Case Consensus forecast4,963196,727237,27419Copper Price-20US$3.90/lb Cu3,218154,807195,43316Copper Price+20US$5.86/lb Cu6,688238,632289,09922Gold Price-20US$2,618.08/oz3,625165,223195,53916Gold Price+20US$3,927.12/oz6,289228,222278,99622Metal Prices-20All metal prices1,708103,165142,99311Metal Prices+20All metal prices8,1182710,2333211,44426Initial CAPEX+20Variable per Scenario4,448166,222196,73216OPEX+20Variable per Scenario3,660165,438205,59116Scandium Oxide Price-40US$900/kg Sc2O3 6,49618Scandium Oxide Price+40US$2,100/kg Sc2O3 8,05020 MINERAL RESOURCE ESTIMATEDoubleview Gold Corp announced an update of the Mineral Resource estimate (MRE). This estimate followed the Micon International Ltd. (Micon) Mineral Resource estimate with an effective date of July 17, 2024. This MRE incorporates significant new data from the 2024 and 2025 exploration campaigns, with an effective date of February 4, 2026, and superseded the 2024 Micon estimate.Table 5: Hat MRE at a 0.2% CuEq Cut-Off Effective February 4, 2026Mineral Resource ClassificationTonnage(Mt)Average GradeMetal ContentCuEq(%)Cu(%)Au(g/t)Co(g/t)Ag(g/t)CuEq(Blb)Cu(Blb)Au(Moz)Co(Mlb)Ag(Moz)Measured2720.440.220.1876.260.372.611.111.4135.62.17Indicated3370.430.210.1976.810.393.211.311.8144.52.88Total M+I6090.430.210.1876.570.385.822.423.2280.15.05Inferred5030.410.180.1976.620.384.571.722.7766.24.19 Table 6: Hat MRE at a 0.2% CuEq Cut-Off as of February 4, 2026, Scandium Oxide ResourcesMineral Resource ClassificationTonnage(Mt)Sc Tonnage1(Mt)Average GradeSc (g/t)Metal ContentSc2O3 2 (t)Measured2723428.791,081Indicated3374228.761,334Total M+I6097628.772,415Inferred5036328.691,996 Notes: 1 Scandium tonnages represent 12.5% of the mineralized material by category, reflecting the proportion of tailings expected to be processed through a dedicated scandium leach circuit under current metallurgical design constraints.2 Scandium oxide metal content have been calculated using the metallurgical recovery of 72% and conversion factor from Sc to Sc2O3 of 1.534. Mineit's Qualified Person, Tomasz Wawruch, FAusIMM, completed the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a senior geology and mineral resource consultant independent of Doubleview. Mr. Gilles Arseneau, PhD., P.Geo., of ARSENEAU Consulting Services Inc., provided an independent review of this MRE.Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.Inferred Mineral Resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. The Mineral Resource Estimate was prepared in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards for Mineral Resources and Mineral Reserves (2014), and CIM MRMR Best Practice Guidelines (2019).The effective date of the MRE is February 4, 2026.Metal contents have been calculated using the following metallurgical recovery factors: Cu = 85%, Au = 89%, Co = 78%, and Ag = 68%.Economic assumptions used include US4.80/lb Cu, US20.00/lb Co, US3,200/oz Au, US46/oz Ag, and a 2% NSR royalty.Mineral Resources are reported within optimized open pit constraints and 0.2% CuEq cut-off grade, based on a C7.93/t milled processing cost and C2.90/t milled general and administrative cost, with a mining cost of C3.01/t plus incremental mining cost increasing by C0.015/t for every bench below the reference level of 1,125 mRL.CuEq calculations do not include scandium. The formula used to calculate CuEq is: CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85))/(4.8 × 22.0462 × 0.85)], where all input variables are expressed in (ppm) and CuEq is expressed in percent (%).Rounding may result in minor variations between individual values and totals; such differences are not considered material to the MRE.Mineral Resource classification reflects the level of geological confidence and satisfies the uncertainty criteria appropriate for exploration and resource development. Additional drilling will be required to reduce uncertainty to the level expected for production planning. The MRE reflects the geological interpretation, drill-hole spacing, and estimation parameters available at the time of modelling. Any additional drilling is expected to influence the current outcome by improving confidence in the estimates and refining the geometry of the mineralized domains.The Mineral Resource results are presented in situ within the optimized pit. Mineralized material outside the pit has not been considered as a part of the current MRE tabulation. Calculations used metric units (metres, tonnes, g/t).A total of 97 diamond drill holes, comprising 49,548 m of core, were incorporated into the Mineral Resource Estimate. All drilling data used in the MRE were subject to standard QA/QC validation prior to inclusion.PROCESSING SCENARIOSThe PEA evaluates two processing scenarios: (A) a conventional Cu-Au-Ag-Co flotation concentrator at 120,000 t/d (42 Mt/a) with two recovery cases-A1 based on metallurgical testwork completed by Sepro Laboratories (Langley, BC) and A2 reflecting target/expected performance-and (B) a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit.The concentrator consists of crushing, grinding, flotation, concentrate handling, and tailings management, producing both a saleable approximately 25% Cu concentrate with co-product gold and by-product silver-cobalt credits and a pyrite concentrate enriched in cobalt; in the full-circuit case, the pyrite concentrate is roasted to generate sulphuric acid and a calcine that is then processed to recover cobalt, gold, silver, and copper; after stripping it will be precipitated as a sulphide to be admixed to the copper concentrate to improve grade, with the acid used to leach flotation tailings for scandium recovery, noting that the scandium circuit is a newer chemical process compared with the otherwise industry-standard flowsheet.Under A1 or A2 (Figure 1), the flowsheet produces a single saleable product-a copper concentrate with payable gold credits; the pyrite concentrate is not treated or marketed in this case and is only processed in B where the hydrometallurgical circuit enables recovery of cobalt (and additional Au-Ag) and supports the scandium circuit (Figure 2), which is planned to be constructed in a phased approach commencing in Year 3 of operations.Figure 1: Grinding and Flotation Flowsheet; Scenarios A1/A2 Report Copper Concentrate Only, while the Cobalt-Pyrite Flotation Stream Shown Is Included Only in Scenario BTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_doubleview1.jpgFigure 2: Scenario B Hydrometallurgical Plant Block Flow Diagram, Showing Downstream Treatment of the Cobalt-Pyrite Stream and Flotation of Tailings to Recover Cobalt (and Au-Ag) and Scandium, Including Sulphuric Acid Generation to Support the Scandium CircuitTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_94c53b19649fcaba_003full.jpgTable 7 summarizes the head grades, concentrate grades, and overall metallurgical recoveries from early testwork for the full circuit; A1 assumes only the reported recoveries to the Cu-Au concentrate, while the cobalt-pyrite concentrate and downstream recoveries are considered only in B.Early metallurgical testwork comprised metallurgical characterization studies under standard laboratory conditions to demonstrate metals recoverability for inclusion in the estimate of CuEq. No attempt was made to optimize flotation conditions, and more advanced flotation testwork was not undertaken. Consequently, the reported metallurgical recoveries are considered conservative, and it is reasonable to expect improvement with further testwork.A2, assumes improved copper and gold recoveries of 89% and 75%, respectively, reflecting expected performance from comparable Cu-Au porphyry flotation circuits following further optimization and testwork.Table 8 summarizes the recoveries assumption on each scenario.CAPITAL COST SUMMARYTable 9 presents the estimated capital cost breakdown for the three evaluated scenarios, separating initial CAPEX from sustaining CAPEX and reporting costs in C$M by major cost area (processing plant, mining, pre-stripping, infrastructure, tailings and water management, Indirects/EPCM, and contingency).Total initial CAPEX is estimated at C$3,552 million (A1), C$3,601 million (A2), and C$3,828 million (B), reflecting the higher processing plant scope and associated indirects/contingency in Scenario B.Total sustaining CAPEX is estimated at C$2,755 million (A1/A2) and C$4,006 million (B), with the increase in B driven primarily by the inclusion of the hydrometallurgical plant and scandium recovery circuit within sustaining capital, while mining, infrastructure, and tailings sustaining components remain broadly consistent across scenarios.OPERATING COST SUMMARYTable 10 summarizes the key operating cost and selling terms used in the PEA, reporting unit costs in C$/t moved, C$/t milled, and (where applicable) C$/kg of scandium oxide, together with concentrate transport and selling costs, TC/RC, and payability assumptions.Average site operating costs are estimated at C$16.22/t milled for Scenario A (concentrate-only) and C$21.92/t milled for B, with the increase in B driven by the addition of hydrometallurgical processing and acid generation (C$3.09/t milled) and scandium oxide processing costs (C$939.55/kg Sc₂O₃).On a payable metal basis, the study reports C1 cash costs of C$2.4/lb CuEq (A1), C$2.39/lb CuEq (A2), and C$2.89/lb CuEq (B) and AISC of C$2.79/lb CuEq (A1), C$2.78/lb CuEq (A2), and C$3.39/lb CuEq (B), reflecting the combined effects of recoveries, co-product/by-product credits, and the additional operating requirements of the full circuit.ECONOMIC RESULTSTable 11 summarizes the key economic assumptions and resulting financial metrics for Scenarios A1, A2, B, including the long-term price deck, cash flow generation, taxation, and discounted valuation at a 5% discount rate. Using an exchange rate of 1.37 CAD: 1.00 USD and long-term prices of US$4.88/lb Cu, US$3,272.60/oz Au, US$50.22/oz Ag, and US$19.57/lb Co (and US$1,500/kg Sc₂O₃ for B), the Project generates average annual EBITDA of C$886 million (A1), C$1,071 million (A2), and C$1,284 million (B). On a post-tax basis, NPV(5%) is estimated at C$4,963 million (A1), C$6,727 million (A2), and C$7,274 million (B) with corresponding post-tax IRRs of 19%, 23%, and 19%, and post-tax payback in Year 6 (A1), Year 5 (A2), and Year 7 (B). Total post-tax free cash flow is estimated at C$10,050 million (A1), C$12,961 million (A2), and C$15,437 million (B), reflecting the higher cash generation under the improved recovery case (A2) and the additional revenue streams in Scenario B, partially offset by the added capital and operating requirements of the hydrometallurgical and scandium circuits.SENSITIVITY ANALYSISSensitivity cases were evaluated for the key value drivers using after-tax NPV (5%) and after-tax IRR, including ±20% copper and gold prices, +20% initial capital, +20% operating costs and, for B, a ±40% scandium price sensitivity.Overall, the sensitivity analysis demonstrates that the Project's after-tax economics remain positive across the tested ranges, with the greatest variability in after-tax NPV(5%) and IRR driven by simultaneous changes in the overall metal price deck. Changes to copper and gold prices individually have a meaningful but smaller effect, while +20% initial CAPEX and +20% OPEX reduce value but do not eliminate Project attractiveness in any of the evaluated scenarios. Scenario B shows additional exposure to scandium oxide price, with after-tax NPV(5%) varying within a narrower range relative to the broader multi-metal price cases, indicating that scandium provides incremental upside while the base-case Cu-Au Project remains financially robust on its own.PERMITTING, RISKS, AND NEXT STEPSPermitting and EnvironmentalPermitting StatusThe permitting process will be supported by the continuation of environmental baseline studies, progression of engineering designs, and the initiation of socio-economic and cultural baseline studies.Due to the anticipated rate of resource extraction, it is expected that the Hat Project will be subject to both federal and provincial impact assessment pathways, so submission to both the Impact Assessment Agency of Canada (IAAC) and British Columbia Environmental Assessment Office (B.C. EAO) for their review is currently anticipated. Agency determination will decide the appropriate level of agency collaboration under the existing cooperation agreement for the Hat Project to acquire a provincial Environmental Assessment Certificate (EAC) and/or federal Decision Statement.The company will also submit a Joint Mines Act and Environmental Management Act Application through the B.C. Major Mines Office. Additional federal authorizations, including Fisheries Act approvals and compliance with Metal and Diamond Mines Effluent Regulations (MDMER), and applicable provincial permits will be obtained concurrently with other assessment and permitting steps. This will not only support protection of the immediate environment through the life of the Project but also respect the rights of First Nations and promote social and economic wellbeing for local communities.Tailings and Water ManagementThe Tailings Storage Facility (TSF) includes a perimeter dyke primarily constructed from compacted cycloned sand. This material will be sourced from the coarse underflow of tailings processed through an on-site cyclone plant. Using the centreline raise method, the dam is designed to be free-draining, lowering the phreatic surface to facilitate geotechnical stability. During operations, seepage from the TSF will be directed to the process plant as reclaim water. Upon closure, the supernatant pond will be drained, and the tailings and dam surfaces will be reclaimed with a granular trafficability layer, followed by a growth medium and native revegetation.The water management strategy prioritizes the reuse of site-impacted water, directing TSF water, contact water from the waste rock storage facilities, and open-pit dewatering to the process plant for use as make-up water.Key Risks and OpportunitiesProject-wideTailings Storage Facility:The location and geometry of the TSF are subject to refinement following geotechnical investigations of the potential site areas. Similarly, the anticipated availability of cycloned sand and the storage requirements for the facility may be adjusted once laboratory testing of the tailings is conducted.The integration of this future site-specific data presents a significant opportunity to optimize the TSF design.Mineral Processing:Limited metallurgical and comminution data introduce uncertainty in equipment sizing and operating cost inputs; however, early results indicate the ore should be amenable to conventional Cu-Au flotation, with potential upside from improved recoveries and reduced reagent consumption through optimization.The scandium circuit is less mature and is sensitive to acid economics and hydrometallurgical performance, but offers meaningful value upside if recoveries, product quality, and operating stability are confirmed at larger scale.Mine Design:Pit slope design criteria and mine scheduling are subject to elevated uncertainty due to the limited geotechnical database, including incomplete definition of structural controls, rock mass variability, and groundwater conditions. This creates downside risk to slope angles, strip ratio, and operating conditions if adverse structures or hydrogeology are encountered; however, it also provides a clear opportunity to materially improve design confidence and potentially optimize slope geometry, mine sequencing, and dewatering requirements through focused data acquisition and updated analyses.Capital Cost estimates:As a PEA-level estimate, capital costs remain subject to the inherent uncertainty of a preliminary design basis and limited engineering definition; however, significant effort was undertaken to develop the estimate using a defined scope, preliminary equipment sizing, and factored/benchmark-based costing with appropriate indirects and contingency. This work provides a credible foundation for decision-making at this stage while also highlighting clear opportunities to optimize capital intensity through further engineering definition, value engineering, and targeted trade-off studies (e.g., comminution configuration, tailings strategy, infrastructure/power, and construction execution approach).Scandium specific:Scandium provides strategic upside given its small, concentrated global supply base and the growing premium placed on secure, qualified supply, but it carries higher execution and commercial risk due to limited scale-up testwork (variability, impurity control, reagent intensity), added residue-management and permitting complexity, and uncertainty around product specifications, pricing, and customer qualification.Next StepsResource:The Company is advancing the Project toward Pre-Feasibility by upgrading confidence in the current Mineral Resource estimate and improving definition of mineralization within the proposed mine plan area. The program will prioritize infill drilling to support conversion of Inferred Resources to Indicated (and, where appropriate, Measured), together with step-out drilling to test extensions of known mineralization and provide improved geological continuity for next-stage mine design, scheduling, and economic evaluation.Waste facilities:Field investigations will be conducted at potential TSF and waste rock storage sites to characterize subsurface conditions and identify suitable borrow materials for construction. These efforts will be supported by site-specific geotechnical and geochemical characterization of the tailings and waste rock. These data sets will inform a TSF design update to a Pre-Feasibility Study (PFS) level of engineering, encompassing an optimized siting and technology trade-off study.Metallurgy:Complete a comprehensive metallurgical testwork program on representative samples including comminution testwork (Bond Work Index, abrasion index, and related grindability tests) and metallurgical variability + locked-cycle flotation testing to define an optimal process flowsheet, mass balance, and optimized reagent scheme, and to produce samples for concentrate dewatering and preliminary smelter marketing.Progress the scandium work through targeted hydrometallurgical optimization including pulp density, free acidity/acid consumption, SX staging and extractant concentration, followed by an integrated pilot trial on bulk samples to validate scandium recovery, product quality, and circuit operability.Mine Design:A phased geotechnical program is recommended that includes re-analysis of existing boreholes (re-logging and detailed structural mapping, including oriented-core interpretation where available), establishment of geotechnical domains, targeted drilling and field mapping to confirm discontinuity sets and persistence, and hydrogeological data collection to constrain pore pressures and inflows. These data will support updated kinematic assessments and slope design analyses, refinement of inter-ramp and overall slope angles, and improved inputs to mine planning, risk management measures, and capital/operating cost estimates.Capital Costs Estimation:As the Project advances to PFS, the estimate will be progressively refined by advancing engineering to a higher level of definition, updating quantities and vendor inputs for major equipment and packages, tightening indirects and construction productivity assumptions, and executing focused optimization and constructability reviews to reduce contingency and improve overall cost confidence.NI 43-101 DISCLOSURE, QUALIFIED PERSONS, AND CAUTIONARY STATEMENTSQualified PersonsThe scientific and technical information in this news release has been reviewed and approved by the following Qualified Persons, each with respect to the matters within their area of expertise, (as defined under NI 43-101):Tomasz Wawruch, FAusIMM, Senior Geology and Mineral Resource Consultant of Mineit Consulting Inc. (responsible for the Mineral Resource estimate).Andrew Carter, EUR ING, B.Sc., CEng., MIMMM (QMR), MSAIMM, SME, of Magister Metallurgy (responsible for metallurgical studies and recovery processes).Shervin Teymouri, P.Eng., Mining Engineer of Mineit Consulting Inc. (responsible for project management, mining engineering, capital and operating cost estimates, and financial analysis).Andre de Ruijter, P.Eng., of Mineit Consulting Inc, (process design, process capital and operating cost lead).Franky Li, P.Eng., of EMM Consulting Pty Ltd (responsible for tailings management and TSF design, tailings capital and operating cost).Jayesh Rami, P.Eng., Infrastructure Engineer of Sacre-Davey Engineering Inc. (responsible for project infrastructure).Qualified Person ReviewThe scientific and technical information contained in this news release has been reviewed and approved by Shervin Teymouri, P.Eng., a Qualified Person as defined under National Instrument 43-101. Mr. Teymouri is a mining engineer and is independent of the Company.Preliminary Economic Assessment Cautionary StatementThe Preliminary Economic Assessment (PEA) for the Hat Project is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability. The PEA provides a conceptual mine plan and is based on low-level technical and economic assessments that are insufficient to support an evaluation of the economic viability of the Project or to establish Mineral Reserves. There is no certainty that the results of the PEA will be realized. Further exploration and site-specific engineering studies are required before a higher level of confidence can be established for the Project's economics.The economic analysis in the PEA is based on several assumptions including, but not limited to, long-term metal prices, foreign exchange rates, metallurgical recoveries, and capital and operating cost estimates. These assumptions are subject to significant risks and uncertainties, and actual results may differ materially from those projected. Readers are cautioned not to place undue reliance on the PEA or the forward-looking information contained in this release.Forward-Looking InformationCertain of the statements made and information contained herein may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Often, these forward-looking statements can be identified using words such as "anticipates," "believes," "continue," "estimates," "expects," "forecasts," "intends," "plans," "projected," or the negatives thereof or variations of such words and phrases. Forward-looking statements in this news release include, but are not limited to, statements with respect to: the results of the Preliminary Economic Assessment for the Hat Project; the estimation of mineral resources; anticipated annual production of copper, gold, cobalt, and scandium; the after-tax NPV and IRR of the Project; forecasted AISC and Total Cash Costs; estimated initial and sustaining capital costs; the timing of a Pre-Feasibility Study; the timeline for permitting milestones and construction decisions; planned early works and infrastructure upgrades; and the Company's ability to maintain strong community and First Nations partnerships.Forward-looking statements are based on a number of assumptions that management considers reasonable at the time they are made, including assumptions regarding: the future prices of copper, gold, cobalt, and scandium; foreign exchange rates; metallurgical recoveries; the cost of essential consumables; and the geopolitical and regulatory climate in British Columbia. However, such statements involve known and unknown risks and uncertainties which may cause actual results to differ materially. These risks include but are not limited to inaccurate estimation of mineral resources; volatility in metal prices; the results of future exploration and development activities; liquidity and financing risks; failure to obtain necessary permits; geotechnical conditions; and changes in applicable mining laws. The PEA is preliminary in nature and includes Inferred mineral resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves. Except as required by law, the Company undertakes no obligation to update or revise forward-looking information as conditions change.Non-GAAP Financial MeasuresThe Company has included certain performance measures in this news release that are not specified, defined, or determined under Generally Accepted Accounting Principles (GAAP). These non-GAAP measures are common in the mining industry but do not have standardized definitions and may not be comparable to similar measures presented by other issuers. Readers should not consider these measures in isolation or as a substitute for performance measures prepared in accordance with GAAP.Total Cash Costs: The Company calculates total cash costs as the sum of mining, processing, refining and transport, G&A, and royalty costs. Cash costs per unit are calculated by dividing the total cash costs by the payable Copper Equivalent (CuEq) units.All-In Sustaining Cost: AISC is a non-GAAP financial measure comprising of total cash costs, sustaining capital expenditures to support ongoing operations, and closure costs. AISC per unit is calculated by dividing the total all-in sustaining costs by the payable CuEq units.Sustaining Capital: This is a supplementary financial measure reflecting cash-basis expenditures expected to maintain operations and sustain production levels over the life of the mine.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX Venture Exchange (TSXV: DBG), the OTCQB (DBLVF), the Berlin Stock Exchange (GER: A1W038), and the Frankfurt Stock Exchange (1D4). Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties-collectively critical minerals-and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.About Mineit Consulting Inc.Mineit Consulting Inc. (Mineit) is an independent mining engineering consulting company providing specialized expertise in project management, geological modelling, Mineral Resource estimation, mining engineering, metallurgical, and process engineering. Mineit led and prepared the Hat Project MRE and PEA, with assistance from other engineering firms, for the Hat Project in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards on Mineral Resources and Reserves.For further information, please contact:Doubleview Gold CorpVancouver, BCFarshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289584 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
在2026年Gartner(R)《供应链规划解决方案魔力象限(TM):流程工业》报告中,OMP在“愿景完整性”和“执行能力”两项指标上均位居最高位置 ACN Newswire

在2026年Gartner(R)《供应链规划解决方案魔力象限(TM):流程工业》报告中,OMP在“愿景完整性”和“执行能力”两项指标上均位居最高位置

比利时安特卫普, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 这是该公司第11次获评“领导者”。OMP认为,这一认可彰显了其持续交付创新解决方案的能力,例如UnisonIQ和Unison决策导向型规划。这反映了市场正向人工智能驱动的供应链规划转型,以及市场对能够实时整合战略、执行与智能的平台日益增长的需求。为最复杂的供应链需求推进智能规划OMP 凭借其久经考验的端到端平台 Unison Planning™,持续推动供应链规划的发展,并赢得了阿斯利康、巴斯夫、强生和宝洁等《财富》500 强企业的信赖。该平台采用开放、云原生及AI驱动的设计,旨在满足流程型和离散型全球供应链的不断演变的需求,涵盖化工、消费品、生命科学、纸张与包装、轮胎与建筑产品以及金属等行业。Unison Planning™ 集成了 UnisonIQ——OMP 的 AI 协调器,它将 AI 代理、助手和引擎整合到一个强大的框架中。UnisonIQ专为供应链规划的“智能代理时代”而设计,在整个平台中嵌入持续智能,为组织提供基于深厚行业专业知识的主动、自主决策基础。“智能代理AI正在从根本上重塑供应链的运营与竞争方式,”OMP首席执行官Paul Vanvuchelen表示。“拥抱这一变革的组织将把市场波动转化为战略优势。”加速整个供应链的决策速度OMP的Unison决策中心规划通过整合人类专业知识、先进AI、实时智能和快速场景评估,提升供应链绩效,从而推动企业范围内的决策速度并提高决策质量。“凭借全面的供应链智能和人工智能驱动的预判能力,Unison决策中心规划使企业能够更早地预见中断情况,评估其影响,并清晰而自信地制定下一步行动,”OMP首席商务与市场官菲利普·弗洛塞姆(Philip Vervloesem)表示。关于Gartner魔力象限2026年3月发布的《2026年Gartner流程工业供应链规划解决方案魔力象限》报告,基于供应商的“执行能力”和“愿景完整性”进行评估,帮助全球企业在复杂且快速演变的市场中甄选合适的合作伙伴。我们认为,这一认可与 OMP 在《2026 年 Gartner 流程工业供应链规划解决方案关键能力报告》中的优异表现相辅相成——在该报告中,OMP 在所有应用场景中均位列前两名。此外,OMP 在 Gartner Peer Insights™ 上持续获得客户的高度评价,这反映了企业用户的积极反馈。如需进一步了解 OMP 在 Gartner 魔力象限中的领导者地位以及供应链规划的未来,请阅读完整报告。在 Gartner 供应链研讨会/博览会™ 上与 OMP 会面OMP 将参加 2026 年 Gartner 供应链研讨会/博览会™,届时客户将分享关于智能、以决策为中心的供应链的实用见解:宝洁公司将在 Symposium/Xpo™ 美国站分享其与 OMP 合作的关键经验,重点阐述集成规划与端到端可视性如何带来可衡量的业务影响。阿斯利康公司将在 Symposium/Xpo™ 欧洲、中东和非洲(EMEA)站展示其迈向以决策为中心的自主规划之旅,重点介绍该公司如何通过转型流程和能力来实现卓越运营。关于 OMPOMP 通过提供市场上最优秀的数字化供应链规划解决方案,助力面临复杂规划挑战的企业脱颖而出、实现增长并蓬勃发展。来自消费品、生命科学、化工、金属、造纸、塑料与包装、轮胎及建筑产品等众多行业的数百家客户,均受益于 OMP 独特的 Unison Planning™ 解决方案。Gartner,《供应链规划解决方案魔力象限》,Pia Orup Lund、Joe Graham、Buse Aras、Jan Snoeckx、Eva Dawkins、Julia von Massow,2026年3月18日。Gartner,《供应链规划解决方案关键能力:流程工业》,Julia von Massow、Eva Dawkins、Jan Snoeckx、Buse Aras、Joe Graham、Pia Orup Lund,2026年3月18日。Gartner和魔力象限(Magic Quadrant)是Gartner, Inc.及其关联公司的商标。Gartner 并不对其出版物中提及的任何公司、供应商、产品或服务予以背书,也不建议技术用户仅选择评级最高或获得其他认定的供应商。Gartner 出版物包含 Gartner 商业与技术洞察部门的观点,不应被视为事实陈述。对于本出版物,Gartner 不作任何明示或暗示的保证,包括对适销性或适用于特定目的的任何保证。Gartner Peer Insights 内容包含基于个人终端用户自身体验的观点,不应被视为事实陈述,亦不代表 Gartner 或其关联公司的观点。Gartner 不对该内容中提及的任何供应商、产品或服务予以背书,亦不对该内容的准确性或完整性作出任何明示或暗示的保证,包括适销性或适用于特定目的的保证。解决方案与产品咨询联系 OMP媒体咨询Kira Perdue (Carabiner)来源:OMP Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries ACN Newswire

OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries

ANTWERPEN, BELGIUM, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - This marks the 11th time the company has been recognized as a Leader. OMP believes this recognition underscores its consistent delivery of innovative solutions such as UnisonIQ and Unison Decision-Centric Planning. It reflects a market shift toward AI-driven supply chain planning, and the growing demand for platforms that unify strategy, execution, and intelligence in real time.Advancing intelligent planning for the most complex supply chain needsTrusted by Fortune 500 leaders such as AstraZeneca, BASF, Johnson & Johnson, and Procter & Gamble, OMP continues to advance supply chain planning through Unison Planning™, its proven end-to-end platform. Open, cloud-native, and AI-driven, the platform is built to meet the evolving demands of process and discrete global supply chains, including chemicals, consumer goods, life sciences, paper and packaging, tires and building products, and metals.Unison Planning™ incorporates UnisonIQ, OMP's AI orchestrator that unifies AI agents, assistants, and engines into one powerful framework. Designed for the agentic age of supply chain planning, UnisonIQ embeds continuous intelligence throughout the platform, giving organizations a foundation for proactive, autonomous decision-making grounded in deep industry expertise."Agentic AI is fundamentally reshaping how supply chains operate and compete," says Paul Vanvuchelen, Chief Executive Officer at OMP. "Organizations that embrace this shift will turn volatility into strategic advantage."Accelerating decision velocity for the entire supply chainOMP's Unison Decision‑Centric Planning elevates supply chain performance by uniting human expertise, advanced AI, real‑time intelligence, and rapid scenario evaluation to drive decision velocity and improve decision quality across the enterprise."With comprehensive supply chain intelligence and AI-powered anticipation, Unison Decision-Centric Planning enables organizations to gain earlier visibility into disruption, evaluate its impact, and prepare the next move with clarity and confidence," says Philip Vervloesem, Chief Commercial & Markets Officer at OMP.About the Gartner Magic QuadrantThe 2026 Gartner Magic Quadrant for Supply Chain Planning Solutions: Process Industries, released in March 2026, evaluates vendors based on their Ability to Execute and Completeness of Vision, helping global companies identify the right partners in a complex and fast-evolving market.We believe this recognition comes alongside OMP's strong performance in the 2026 Gartner Critical Capabilities for Supply Chain Planning Solutions Process Industries report, where it had been ranked in the highest two positions across all Use Cases. OMP also continues to receive strong customer ratings on Gartner Peer Insights™, reflecting positive feedback from enterprise users.For more information about OMP's position as a Leader in the Gartner Magic Quadrant and the future of supply chain planning, read the full report.Meet OMP at the Gartner Supply Chain Symposium/Xpo™OMP will participate in the 2026 Gartner Supply Chain Symposium/Xpo™, where customers will share practical insights on intelligent, decision-centric supply chains:Procter & Gamble will present key learnings from its collaboration with OMP at the Symposium/Xpo™ US, highlighting how integrated planning and end-to-end visibility drive measurable business impact.AstraZeneca will present its journey toward decision-centric autonomous planning at the Symposium/Xpo™ EMEA, highlighting how it is transforming processes and capabilities to achieve excellence.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, plastics & packaging, tires and building products - benefit from using OMP's unique Unison Planning™.Gartner, Magic Quadrant for Supply Chain Planning Solutions, Pia Orup Lund, Joe Graham, Buse Aras, Jan Snoeckx, Eva Dawkins, Julia von Massow, 18 March 2026.Gartner, Critical Capabilities for Supply Chain Planning Solutions: Process Industries, Julia von Massow, Eva Dawkins, Jan Snoeckx, Buse Aras, Joe Graham, Pia Orup Lund, 18 March 2026.Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Wellgistics Health Inc.签署1.05亿美元意向书,拟评估收购Neuritek Therapeutics, Inc.的可行性,后者致力于开发神经系统及精神疾病的创新疗法 ACN Newswire

Wellgistics Health Inc.签署1.05亿美元意向书,拟评估收购Neuritek Therapeutics, Inc.的可行性,后者致力于开发神经系统及精神疾病的创新疗法

佛罗里达州坦帕市, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - Wellgistics Health, Inc.(“Wellgistics”或“公司”)(纳斯达克代码:WGRX)今日宣布,已签署一份非独家、非约束性的意向书(“LOI”),旨在评估潜在收购专注于神经科学研究的机构Neuritek Therapeutics。若该拟议的全股票交易得以完成,旨在通过扩展其核心技术驱动的药品分销及服务业务周边能力,从而增强Wellgistics现有的创收医疗保健平台。通过其涵盖处方配药、批发分销及人工智能驱动的患者就医解决方案的集成生态系统,Wellgistics将制造商、医疗服务提供者以及遍布全国的独立药房网络紧密连接起来。公司认为,引入一家以研究为导向的机构,将有助于加强药物研发与商业化之间的协同,从而实现与制药合作伙伴的早期对接,提高产品管线透明度,并创造增量收入机会;同时,通过构建更集成、更具差异化的平台,提升长期股东价值。该交易仍需完成尽职调查、最终协议的谈判与签署、各方董事会批准以及满足其他惯常的交割条件。无法保证最终协议将得以签署,亦无法保证拟议交易将按当前设想的条款完成,甚至可能无法完成。该意向书不具约束力,且不强制任何一方完成拟议交易。任何潜在交易的范围、结构及条款仍在评估中,并可能因持续进行的尽职调查和谈判而发生重大变化。作为更广泛增长战略的一部分,本公司亦正在积极评估医疗保健及生命科学领域的其他战略机遇。这些机遇可能包括收购、合作或其他战略交易。无法保证此类举措将最终促成交易。关于 Wellgistics Health, IncWellgistics Health 是一家快速扩张、技术驱动的医疗保健平台,立足于药品分销与患者获取服务的核心位置。公司已构建了一个涵盖批发分销、处方配药及人工智能驱动的获取解决方案的集成化、高性能生态系统,直接连接制药商、医疗服务提供商以及覆盖全美的独立药房网络。通过整合基础设施、数据和智能自动化,Wellgistics正实施一种资本高效的运营模式,旨在在庞大且分散的医疗保健市场中占据显著份额。公司致力于拓展高利润率收入来源、深化与制造商的战略合作关系,并在整个平台推动运营杠杆效应。凭借差异化的端到端服务和严谨的执行力,Wellgistics 已做好准备加速增长、提升盈利可见度,并为股东创造超额的长期价值。关于 Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. 开发了一种基于生物机制的下一代疗法,旨在治疗创伤后应激障碍(PTSD)的根本原因。Neuritek 率先上市的疗法是一种口服活性脂肪酸酰胺水解酶 1 型(FAAH1)抑制剂,该酶负责代谢内源性大麻素(AEA),这是首个基于机制的 PTSD 治疗方案。 该公司由威廉·哈普沃斯(William Hapworth)医学博士创立,他不仅是临床研究领域的先驱,还是一位拥有30多年临床经验的执业精神科医生。了解更多信息请访问 www.neuritek.com ,或在 LinkedIn 关注 neuritek-therapeutics-inc 参与讨论前瞻性陈述本新闻稿包含《1995年私人证券诉讼改革法案》及其他适用联邦证券法所界定的前瞻性陈述。这些前瞻性陈述包括但不限于以下内容:关于潜在收购Neuritek Therapeutics, Inc.(“Neuritek”)的陈述,包括任何交易的预期结构、估值、时间安排及完成可能性;意向书的初步性和非约束性;此类交易可能带来的战略、运营及财务效益; 本公司协商并签订最终协议的能力;本公司获取任何必要融资的能力;任何被收购业务的整合;以及本公司的整体增长战略和未来业绩。前瞻性陈述可通过“可能”、“可能”、“将会”、“应该”、“预期”、“预计”、“相信”、“打算”、“计划”、“预测”、“估计”、“潜在” “机会”、“目标”、“预测”、“继续”、“将”以及类似表述。这些前瞻性陈述基于当前的预期、假设和估计,并受重大风险和不确定性的影响,其中许多因素超出本公司的控制范围。可能导致实际结果与预期存在重大差异的重要因素包括但不限于:各方未能签订最终协议的风险;意向书被终止或未能促成交易完成的风险;拟议估值及交易条款仅为初步性质且可能发生重大变化的不确定性;未能以可接受的条款获得所需融资或根本无法获得融资的风险; 任何交易预期收益未能实现的风险;将以研发为主的组织整合至本公司现有业务的相关风险;药品或治疗产品的开发、测试、监管审批及商业化相关风险,包括临床结果不佳或出现延误的可能性;监管及合规风险;以及本公司不时向美国证券交易委员会提交的文件中所述的其他风险和不确定性。前瞻性陈述仅反映其作出之日的观点,不应过度依赖此类陈述。除适用法律要求外,本公司不承担更新或修订任何前瞻性陈述的义务。Wellgistics 媒体与投资者联系方式媒体:media@wellgisticshealth.com 投资者关系: IR@wellgisticshealth.com 来源:Wellgistics Health, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders ACN Newswire

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

TAMPA, FLA., Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.About Wellgistics Health, IncWellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.About Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-incForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share ACN Newswire

Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share

Key Results Highlights:- Revenue Growth: 8.6% increase to approximately HK$1,813.8 million- Net Profit Increase: 3.5% rise to HK$318.1 million, driven by operational efficiency- Final Dividend: Proposed final dividend of HK7.0 cents per share, bringing total dividend for 2025 to HK14.0 cents per share, a 16.7% surge from HK12.0 cents in 2024- Net Cash & Cash Equivalents: HK$782.7 million (HK$557.2 million as at 31st December 2024)Regulatory Milestones:- NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops approved in July 2025; multi-dose Sodium Hyaluronate Eye Drops approved in January 2026 for registration and commercialisation in the PRC- BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA in August 2025, marking a crucial regulatory milestoneBusiness Developments:- Exclusive Distribution (Seefunge): Exclusive distribution of Seefunge's Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops in the PRC- Exclusive Distribution (Osteopore): Exclusive distribution of Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau.- Collaboration with Airdoc: Joint operation of Artificial Intelligence-based retinal businesses in the PRC- Strategic Collaboration with Kenvue: Promotion and marketing of Kenvue's consumer health products (Rhinocort(R), Motrin(R), Tylenol(R)) in the PRC.- International Innovation Accelerator: Signed MOU with Suzhou Industrial Park to launch cross-border life sciences accelerator.- First Overseas Market Entry: Beifushu(R) introduced to Singapore via Special Access Route at Singapore National Eye Centre.Intellectual Property and Market Presence:- Robust IP Portfolio: 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.- Extensive Distribution Network: Products available in over 14,600 hospitals and medical providers, and approximately 2,600 pharmaceutical stores across the PRCAwards and Recognition:- 2025 Top 500 Manufacturing Companies in Guangdong Province: Recognises industrial scale and comprehensive competitiveness- National Manufacturing Champion Enterprise: Affirms leading position in specialized biopharmaceutical segment- 2025 "Golden Kunpeng" China Financial Value Ranking – Most Valuable Listed Company for Investment: Highlights capital market recognition of growth potential- Participation at Asia-Pacific Academy of Ophthalmology Congress 2026: Showcasing key ophthalmology products and pipeline assets, strengthening engagement with regional eye care professionals and institutions.HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor (“rb-bFGF”), today announced robust annual results for the year ended 31st December 2025, with revenue up 8.6% to HK$ 1,813.8 million and net profit up 3.5% YoY to HK$318.1 million. The Group achieved multiple regulatory milestones and expanded its product portfolio through strategic collaborations, and Beifushu’s landmark entry into Singapore. These achievements underscore Essex's commitment to innovation and operational excellence, driving sustained revenue and profit growth.Diversified Growth Fueled by Flagship BiologicsThe Group achieved a consolidated turnover of approximately HK$1,813.8 million, with an increase of 8.6% as compared to approximately HK$1,669.8 million in 2024. Correspondingly, the Group’s profit increased by 3.5% to approximately HK$318.1 million as compared to approximately HK$307.2 million in 2024.The Beifushu(R) series and Beifuji(R) series, the Group’s flagship products drove growth, contributing 83.5% of turnover.The ophthalmology segment (“Ophthalmology”) recorded a turnover of HK$835.0 million, grew 8.2% year-on-year, led by Beifushu(R) unit-dose eye drops and supported by its preservative free design and expanding application scenarios, which cover multiple areas such as dry eye treatment and post-operative recovery, and contributions from Beifushu(R) eye gel, (Iodized Lecithin Capsules) and a range of unit-dose eye drops (Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops).The surgical segment (“Surgical”) turnover rose 1.8% year-on-year to HK$895.9 million, leveraging Beifuji’s broad clinical applications across multiple medical departments and strong market presence. It is also supported by numerous clinical guidelines and expert consensus, thereby laying a solid foundation for future indication expansion and sustained growth. In addition, Group Carisolv(R) dental caries removal gel, PELNACTM collagen-based artificial dermis and SCALGENTM double-layered artificial dermis had further strengthened and contributed to the Surgical business.Notably, Healthcare and Partner Services delivered a total turnover of approximately HK$82.9 million for the year ended 31st December 2025, representing a significant increase of 350% as compared to 2024. The growth was primarily driven by Dr. YaDian oral care products, online and offline healthcare services and CMO/CDMO services.Strengthening Financial Position and Shareholder ReturnsThe Group maintains a healthy financial position, with cash and cash equivalents of approximately HK$782.7 million as of 31st December 2025. Bank borrowings stand at HK$325.6 million, with a manageable repayment schedule over 5 years period. The Group’s gearing ratio is at 30.9% (2024: 28.8%), indicating disciplined financial management and ample liquidity.The Board is pleased to propose a final dividend of HK7.0 cents per ordinary share. Together with the interim dividend of HK7.0 cents per ordinary share, the total dividend for 2025 reaches HK14.0 cents, representing a notable year-on-year increase of 16.7% from HK12.0 cents in 2024, demonstrating the Group’s ongoing commitment to delivering greater returns to its shareholders.Broad Portfolio and Robust Pipeline Fuel Sustained GrowthThe Group’s business comprises three core segments: Ophthalmology, Surgical (wound care and healing) and Healthcare and Partner Services segment, with the Group’s six (6) flagship commercialised biologics, collectively referred to as the “bFGF Series”, which are marketed and sold in the PRC. Three of the bFGF Series were approved by NMPA as Category I drugs, and five are listed on the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance in the PRC.In addition, the Group offers a portfolio of commercialised preservative-free unit-dose eye drops, including Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops. The Group further expanded its ophthalmology franchise by obtaining NMPA approvals for the registration and commercialisation of multi-dose Diquafosol Sodium Eye Drops in July 2025 and multi-dose Sodium Hyaluronate Eye Drops in January 2026. The new launches target the PRC’s growing dry eye treatment market, complementing the Group’s Beifushu(R) ophthalmic repair series.As for the Surgical segment, the Group’s Carisolv(R) dental caries removal gel, Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based artificial dermis, SCALGENTM double-layered artificial dermis and Osteopore’s bioresorbable implants (Osteomesh(R) and Osteoplug(R)), are complementing the Group’s Beifuji(R) wound healing series.Strategic R&D Investment to Capture Emerging Market OpportunitiesThe Group is committed to pragmatically investing in new products and technologies to strengthen its product and R&D pipeline, with a mission to develop groundbreaking therapeutics that address unmet clinical and commercial needs. In 2025, total R&D expenditures were approximately HK$177.2 million, representing 9.8% of the turnover, of which approximately HK$139.3 million were capitalised.During the year, the Group’s Medical Scar Repair Gel obtained NMPA registration approval as a Class II medical device, expanding the Group’s footprint in the fast-growing high-end wound care and medical aesthetics markets, unlocking new growth drivers for long-term success.The global phase 3 clinical project of bevacizumab ophthalmic injection (EB12-20145P) has successfully completed patient enrolment across the PRC, Australia, European Union countries and the United States, with the last patient last visit was completed. A Biologics License Application (BLA) was accepted by NMPA in the PRC in August 2025.To amplify the Group’s presence in the Asia ophthalmic community and accelerate the market launch of new products, the Group participated in the 2026 Asia-Pacific Academy of Ophthalmology (APAO) Congress. The event provided a premium platform to showcase ophthalmic solutions, engage with regional clinical experts and partners, and build momentum for the rollout of its innovative ophthalmic products, reinforcing its global brand influence.The Group holds a total of 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.The Group currently has multiple R&D sites located in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore. These sites support the Group’s efforts to develop new therapeutics and recruit global talent.To date, the Group has 18 R&D programmes ranging from pre-clinical to clinical stages, with several ophthalmology programs currently in the clinical stage, specifically Bevacizumab intravitreal injection, SkQ1 eye drops and Cyclosporine eye dropsBroadening Commercial Reach Through Market Expansion and PartnershipsAs of 31st December 2025, the Group maintains an extensive network of 47 regional sales offices in the PRC and a strategic base in Singapore to facilitate market access into Southeast Asian countries. With a vast distribution network, the Group’s products are prescribed in more than 14,600 hospitals and medical providers, coupled with approximately 2,600 pharmaceutical stores, covering major cities throughout the PRC.During the year under review, the Group achieved multiple landmark breakthroughs in the PRC and overseas market expansion, unlocking new multi-dimensional growth momentum. In the overseas market, the Group’s flagship product Beifushu(R) was successfully introduced to Singapore via the Special Access Route at the Singapore National Eye Centre, marking the product’s first commercial launch beyond the PRC, and establishing a solid foothold to support the Group’s future expansion into Southeast Asia and global markets.In the PRC market, the Group entered into two landmark strategic partnerships during the year: a collaboration with global consumer health leader Kenvue, under which the Group will leverage its extensive nationwide commercial network in the PRC to carry out promotion, medical education and marketing for Kenvue’s selected consumer health products including Rhinocort(R) (Budesonide Nasal Spray), Motrin(R) (Ibuprofen Suspension/Drops), and Tylenol(R) (Paracetamol Drops/Suspension); and an exclusive distribution agreement for Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau, marking a strategic entry into the high-potential stomatology market. The partnerships broaden the Group’s healthcare business footprint, delivering strong synergies with its existing ophthalmology and regenerative medicine lines.To drive sustainable growth and expansion for its current and future products, the Group has been investing relentlessly in enhancing its competitiveness and broadening its reach by expanding the clinical indications for its commercialised products, increasing patient access in lower-tier cities across the PRC, developing complementary sales channels, and nurturing the healthtech e-platform to enhance patient access.The Group’s second factory at Zhuhai Hi-Tech Industrial Park, with a gross floor area of about 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026 -2027.Mr. Patrick Ngiam, Chairman of Essex, said “2025 was a standout year with Beifushu’s landmark entry into Singapore, driving robust growth through flagship products, innovation-focused R&D, and strategic partnerships. Essex remains committed to addressing unmet needs and driving long-term growth.We will proactively and systematically recalibrate operating and distribution costs to mitigate the negative impact on FY26 profit from the increase of VAT from 3% to 13% without disrupting our focus on Group development plans.”About EssexBio (1061.HK)EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,600 hospitals, supported by the Company’s 47 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe ACN Newswire

GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has officially launched its European sales activity. During the week of March 9th, GMG held a kick off training workshop in London where it brought together its new team members from various locations in Europe and UK for technical product and sales training.The GMG European Sales team numbers more than 10 professional sales executives based in Europe and UK who focus on lead generation, inside sales and executive sales business development for GMG's G® Lubricant and THERMAL-XR® products.Figure 1: Members of the GMG European Sales TeamTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/289529_gmg_figure1.jpgSeparately, the Company is also pleased to announce that it has been informed that the G® Lubricant patent in Europe has been accepted to be granted for a period of 20 years.Craig Nicol, CEO & Managing Director of the Company, commented "Building a sales force in key areas of the world is one of GMG's key activities it is focused on right now and to get the European team set up and running so fast has been a great achievement."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "I congratulate the Company on building the European Sales team and look forward to hearing of future success."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the size, term and success of GMG's European sales team and the eventual granting of and successful enforceability of the Company's G® Lubricant patent.Such forward-looking statements are based on a number of assumptions of management, including the European sales team will perform and the Company's G® Lubricant patent will be patented successfully. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that the GMG European Sales team does not successfully drive sales for the Company and the Company's G® Lubricant patent is not patented and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289529 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
亿胜生物科技2025全年业绩稳健 收入升8.6%至18.14亿港元 净利润升3.5%至3.18亿港元 全年股息增加16.7%至每股14港仙 ACN Newswire

亿胜生物科技2025全年业绩稳健 收入升8.6%至18.14亿港元 净利润升3.5%至3.18亿港元 全年股息增加16.7%至每股14港仙

关键业绩摘要:- 收入增长:收入同比增长8.6%至约18.14亿港元- 净利润提升:得益于运营效率,净利润增长3.5%至3.18亿港元- 末期股息:拟派末期股息每股0.07港元,2025年全年股息达每股0.14港元,较2024年全年股息的每股0.12港元大幅增加16.7%- 现金及现金等价物:7.83亿港元(2024年12月31日:5.57亿港元)研发里程碑:- NMPA批准:多剂量地夸磷索钠滴眼液于2025年7月获批;多剂量玻璃酸钠滴眼液于2026年1月获批在中国注册和商业化。- BLA受理:贝伐珠单抗眼内注射液的生物制品许可申请(BLA)于2025年8月获NMPA受理,标志着重要的监管里程碑。商业发展:- 独家代理(视方极):获得浙江视方极富马酸依美斯汀滴眼液、盐酸奥布卡因滴眼液的独家代理权。- 独家代理(Osteopore):获得Osteopore创新的牙科、正畸及颌面产品在中国内地、香港及澳门的独家代理权。- 与鹰瞳科技合作:在中国实现眼底AI业务的联合运营。- 与科赴战略合作:在中国推广及营销科赴的消费者健康产品(雷诺考特(R)、美林(R)、泰诺林(R))。- 国际创新加速器:与苏州工业园区签订战略合作谅解备忘录,推出国际创新加速器。- 首个海外市场准入:贝复舒(R)通过特别采用程序成功引入新加坡国家眼科中心。知识产权与市场布局:- 强大的知识产权组合:持有合共121份专利证书或授权书,包括91项发明专利、15项实用新型专利及15项外观专利。- 广泛的销售网络:产品覆盖中国内地超14,600家医院和医疗机构以及约2,600家药房。奖项与荣誉:- 2025年广东省制造业企业500强:表彰产业规模及综合竞争力- 国家级制造业单项冠军企业:确认在专业生物制药领域的领先地位- 2025"金鲲鹏"中国财经价值榜-最具投资价值上市公司:突显资本市场对增长潜力的认可- 参与2026年亚太眼科学会大会:展示主要眼科产品及在研管线,加强与区域眼科专业人士及机构的联系。香港, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 亿胜生物科技有限公司("亿胜生物"及其附属公司"集团";股份代号:1061.HK),一家领先的生物制药企业,专注于研发、生产和销售基因工程药物重组牛碱性成纤维细胞生长因子("rb-bFGF"),今日公布截至2025年12月31日止的强劲年度业绩。集团收入同比增长8.6%至18.14亿港元,利润同比增长3.5%至3.18亿港元。年内,亿胜生物达成了多项监管里程碑,并通过战略合作扩大了产品组合,同时成功将贝复舒(R)引入新加坡。这些成就彰显了亿胜对创新和卓越运营的承诺,持续推动收入和利润的增长势头。旗舰生物药推动多元化增长集团实现综合营业额约18.14亿港元,较2024年的约16.70亿港元增长8.6%。相应地,集团溢利较2024年的约3.07亿港元增长3.5%至约3.18亿港元。集团的旗舰产品贝复舒(R)系列及贝复济(R)系列持续带动增长,占总营业额的83.5%。眼科分部录得营业额8.35亿港元,同比大幅增长8.2%。其中,单剂量贝复舒(R)滴眼液凭借无防腐剂设计及应用场景的持续拓展(覆盖干眼症治疗及术后修复等多元领域)实现强劲销售增长,贝复舒(R)眼用凝胶、适丽顺(R)(卵磷脂络合碘胶囊)和一系列不含防腐剂单剂量滴眼液(包括妥布霉素、左氧氟沙星、玻璃酸钠、盐酸莫西沙星及地夸磷索钠滴眼液)亦作出持续贡献。外科分部实现营业额8.96亿港元,增长1.8%,主要受惠于贝复济(R)系列产品在多个临床科室的广泛应用及其稳固的市场地位。同时,贝复济(R)系列产品已获多项临床指南及专家共识支持,为未来适应症拓展及持续增长奠定基础。此外,集团的Carisolv(R)龋齿凝胶、皮耐克可吸收性敷料、适可健双层人工真皮修复材料等产品进一步增强并促进了外科业务的发展。值得注意的是,医疗保健及伙伴服务于截至2025年12月31日止年度录得总营业额约8,290万港元,较2024年大幅增长350%。增长主要来源于伢典医生口腔护理产品、线上及线下医疗保健服务及CMO/CDMO服务等。稳健的财务基础和股东回报集团维持稳健的财务状况。截至2025年12月31日,集团录得现金及现金等价物约7.83亿港元。银行借贷为3.26亿港元,将在未来五年内按计划偿还。集团的资产负债比率为30.9%(2024年:28.8%),反映出集团具备严谨的财务管理能力和充足的流动性。董事会欣然建议派发末期股息每股普通股0.07港元。连同中期股息每股普通股0.07港元,2025年全年股息达到0.14港元,较2024年全年股息的0.12港元同比显著增长16.7%,以彰显集团致力于为股东创造价值的承诺。广泛的产品组合及强大的研发管线支持持续增长集团业务由三个核心分部组成:眼科、外科(创伤护理及修复)以及医疗保健及伙伴服务分部。集团拥有六种于中国市场销售的商业化生物制剂,统称"bFGF系列"。其中三种bFGF系列为国家药品监督管理局("NMPA")批准的国家一类新药,五种被列入中国国家基本医疗保险、工伤保险和生育保险药品目录。此外,集团提供一系列商业化的不含防腐剂单剂量滴眼液,包括妥布霉素、左氧氟沙星、玻璃酸钠、盐酸莫西沙星及地夸磷索钠滴眼液。集团进一步拓展其眼科产品组合,分别于2025年7月及2026年1月获得NMPA批准多剂量地夸磷索钠滴眼液及多剂量玻璃酸钠滴眼液在中国注册和商业化。新获批产品聚焦于中国不断增长的干眼治疗市场,以补充集团的贝复舒(R)眼表修复系列产品。外科方面,集团的Carisolv(R)龋齿凝胶及伢典医生口腔护理产品,以及一系列产品及医疗器械(包括紫外线光疗仪、皮耐克可吸收性敷料、Osteopore用于牙科手术的生物可吸收植入物(Osteomesh(R)及Osteoplug(R))及其他用于近视防控的医疗器械),共同补充了集团的贝复济(R)创伤修复系列产品。战略性研发投资以把握新兴市场机遇集团致力于务实地投资新产品及技术,以强化其产品及研发管线,使命是开发解决未满足的临床及商业需求的突破性的疗法。2025年,研发总支出约为1.77亿港元,占营业额的9.8%,其中约1.39亿港元已资本化。年内,集团医用疤痕修复凝胶获批NMPA二类医疗器械注册证,将集团业务拓展至快速增长的高端伤口护理及医疗美容市场,解锁新增长动力以推动长期发展。贝伐珠单抗眼内注射液(EB12-20145P)的全球三期临床项目已成功完成了在中国、澳大利亚、欧盟国家及美国的患者入组,最后一名患者已完成最后一次访视。其生物制品许可申请(BLA)已于2025年8月获中国NMPA受理。为提升集团在亚洲眼科领域的影响力,并加速新产品的市场推出,集团参与了2026年亚太眼科学会(APAO)大会。该会议提供了一个绝佳平台,用以展示眼科解决方案、与区域临床专家和合作伙伴交流,并为集团创新眼科产品的推出积聚动能,从而提升全球品牌影响力。集团持有121份专利证书或授权书,包括91项发明专利、15项实用新型专利及15项外观专利。集团目前于珠海(中国)、波士顿(美国)、伦敦(英国)及新加坡设立多个研发基地。这些基地为集团开发新疗法和招募全球人才提供支援。截至目前,集团共有18项研发计划处于临床前至临床阶段,其中数项眼科项目处于临床阶段,具体包括贝伐珠单抗眼内注射液、SkQ1滴眼液及环孢素滴眼液。透过市场扩张与合作拓宽商业覆盖截至2025年12月31日,集团于中国设有47间地区销售办事处,并于新加坡设有战略基地,以促进其产品进入东南亚市场。凭借庞大的分销网络,集团的治疗产品在中国各地的逾14,600家医院及医疗机构以及约2,600家药房开具处方,覆盖了中国各地的主要城市。回顾年内,集团在国内外市场扩张方面取得了多项里程碑式的突破,解锁了多维度的新增长动力。在海外市场,集团的旗舰产品贝复舒(R)通过特别采用程序成功引入新加坡国家眼科中心,标志着该产品首次进入中国以外地区,为集团未来进军东南亚及全球市场奠定了坚实基础。在国内,集团年内达成了两项具里程碑意义的战略合作:与全球消费者健康领导企业科赴合作,利用集团在中国广泛的全国性商业网络,对科赴精选的消费者健康产品(包括雷诺考特(R)、美林(R)及泰诺林(R))进行推广、学术教育及营销;以及与Osteopore签订独家分销协议,在中国内地、香港及澳门分销其创新的牙科、正畸及颌面产品,标志着集团战略性进军高潜力的口腔科市场。这些合作拓宽了集团医疗保健业务的版图,并与其现有的眼科及再生医学业务产生强大的协同效应。为推动现有及未来产品的可持续增长和扩张,集团一直不懈地进行投资,通过扩大其商业化产品的临床适应症、增加中国较低线城市的患者可及性、开发补充销售渠道,以及培育医疗科技电子平台以增强患者可及性,来提高其竞争力并拓宽覆盖范围。集团位于珠海高新区科技创新海岸的第二间工厂,建筑面积约58,000平方米,用作研发、生产、办公及宿舍,预计将于2026或2027年间完工。亿胜生物主席严名炽先生表示:"2025年对亿胜来说是具有里程碑意义的一年,贝复舒(R)成功引入新加坡,集团亦依托其核心产品、创新研发及战略合作,实现稳健增长。未来,亿胜将继续致力于满足未被满足的临床需求,推动集团长期发展。我们将主动、系统性地优化运营及销售成本,以缓解增值税由3%上调至13%对2026财年利润带来的不利影响,同时保证集团发展规划的稳步推进。"关于亿胜生物(股票代码﹕1061.hk)亿胜生物是一间专注于研发、生产和销售基因工程药物b-bFGF的生物制药企业,拥有包括贝复舒(R)、贝复济(R)、贝复新(R)在内的六种基因工程药物在中国上市销售。此外,公司还拥有包含一系列不含防腐剂单剂量滴眼液和适丽顺(R)卵磷脂络合碘胶囊等的多元化产品组合,主要应用于眼科及皮肤科处方药领域的创伤修复及疾病治疗。这些产品在公司于中国的47个区域办事处的支持下,在逾14,600家医院进行营销和销售。依托自身在生长因子和抗体技术领域的研发平台,亿胜生物在多个临床阶段拥有强大的项目管线,涵盖广泛的领域和适应症。网址: http://www.essexbio.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
云顶新耀达成艾曲帕米鼻喷雾剂资产收购协议 强化心血管领域产品布局 ACN Newswire

云顶新耀达成艾曲帕米鼻喷雾剂资产收购协议 强化心血管领域产品布局

香港, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀宣布与箕星药业香港有限公司(以下简称"箕星药业")达成资产收购协议 (The Asset Purchase Agreement),获得艾曲帕米(Etripamil)鼻喷雾剂(拟定中文商品名:星必妥(R))在大中华区的开发、商业化及产品地产化权益。此次合作是公司深化心血管领域战略布局的重要举措,进一步丰富了公司的产品管线、增强协同效应,持续巩固公司在心血管疾病领域的发展。根据协议,云顶新耀将向箕星药业支付3000万美元(相当于约人民币206,937,000元)首付款,以及最高不超过2000万美元(相当于约人民币137,958,000元)的开发里程碑付款。作为本协议的一部分,云顶新耀将获得箕星药业于2021年5月签订的许可协议及相关附属协议项下的权利、权益、主张、职责、义务及责任(不包括双方约定的部分除外责任)。艾曲帕米鼻喷雾剂是一款新型、速效的钙离子通道阻滞剂,采用便携式鼻喷雾剂给药,起效迅速且耐受性良好,可居家自行使用,可及性高。该药物于2025年12月获得美国食品药品监督管理局(FDA)批准(美国商品名:CARDAMYSTTM),成为30多年来首款且唯一获批用于成人阵发性室上性心动过速(PSVT)急性症状性发作的疗法,开拓了PSVT治疗新场景。患者可在无医疗监督的环境(如居家)自行给药,实现对病情的主动掌控,使疾病管理从依赖急诊干预转向更加主动的院外管理。此外,艾曲帕米鼻喷雾剂正开发用于伴有快速心室率反应的房颤(AFib-RVR)适应症,II期临床研究已取得积极结果,并计划推进III期临床研究,未来有望进一步拓展至更广泛患者人群。在中国,艾曲帕米鼻喷雾剂用于治疗PSVT的新药上市申请已于2025年1月17日获中国国家药品监督管理局(NMPA)正式受理,并预计于2026年第三季度获批,有望为PSVT患者提供全新的治疗选择。PSVT是一种以突发突止为主要特征的心动过速临床综合征,发作时心率极快且节律规则,通常持续数分钟至数小时,患者症状明显且恐惧感强。PSVT急性发作的治疗缺乏安全、便捷、可在院外自行使用的快速终止药物,使患者在发作期长期处于"被动等待"状态,缺乏真正意义上的"按需自救"工具。据悉,在中国,每1000中约有2.3-4人患有PSVT,估计总患者人数为300-600万。AFib-RVR的特征是心率不规则,紊乱且快速,呈渐进式发作且不易自行终止,容易反复持续。目前中国的房颤患病率1.6%,对应患者人数约2000万,并随老龄化加剧呈上升趋势。PSVT与AFib-RVR都会增加患者的失控感和心理负担。整体来看,PSVT及AFib-RVR患者人群规模超过2500万人,临床需求远未得到满足,亟需更便捷、更高效的治疗选择。临床数据方面,此次艾曲帕米鼻喷雾剂获中国NMPA新药上市申请受理是基于艾曲帕米关键性III期 RAPID 研究和中国III期 JX02002 临床研究所取得的数据结果。JX02002研究达到了方案预设的主要终点,治疗期出现的不良事件(TEAEs)在艾曲帕米治疗组和安慰剂组之间相当。艾曲帕米鼻喷雾剂获FDA批准是基于一项扎实的临床试验项目所得出的结论,该项目共收集了来自超1,800名参与者、超2,000次PSVT发作的安全性数据。这包括成功的3期RAPID试验,这是一项在全球范围内开展的、随机、双盲、安慰剂对照研究,结果于2023年发表在《柳叶刀》杂志上。RAPID试验达到了其主要终点:自行使用艾曲帕米的参与者(N=99)中有64%在30分钟内从室上性心动过速转为窦性心律,而安慰剂组(N=85)为31%(HR = 2.62; p
More
同仁堂医养(02667.HK)新股招股:尚在发展早期的中医医疗龙头股 估值几何? ACN Newswire

同仁堂医养(02667.HK)新股招股:尚在发展早期的中医医疗龙头股 估值几何?

香港, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 在中医药文化传承创新发展的时代浪潮中,一家承载着350余年历史积淀的医疗集团正昂首阔步走向国际资本市场。北京同仁堂医养投资股份有限公司(以下简称"同仁堂医养")于2026年3月20日正式启动港股IPO招股,股票代码为02667.HK,招股价范围为7.30港元至8.30港元,中金公司担任独家保荐人,将于3月30日挂牌交易。凭借深厚的品牌底蕴、卓越的医疗服务能力和清晰的战略布局,同仁堂医养向全球投资者展示中国中医医疗服务行业的无限潜力。本次全球发售H股总数为108,153,500股,其中香港公开发售10%,国际发售90%,基石投资占比46.15%,设置绿鞋。对港股投资者而言,这是一个值得注意的机会,中医医疗服务赛道此前仅有固生堂,两者模式在中医细分赛道显现出差异化,未来发展也各有侧重,同仁堂医养的加入将为投资者提供新的配置选择。百年品牌背书,大流量的降维优势作为中华老字号的杰出代表,"同仁堂"品牌始创于1669年,拥有超过350年的历史传承。这份厚重的文化积淀不仅代表着百年品质,更是国人心中标志化的民族品牌,也是其最宝贵的无形资产。招股书显示,按2024年总门诊人次及住院人次计,同仁堂医养是中国非公立中医院医疗服务行业中最大的中医院集团,市场份额达1.7%。按2024年中医医疗服务总收入计,公司以0.2%的市场份额在非公立中医院医疗服务行业中排名第二。这一领先地位的确立,离不开"同仁堂"金字招牌的强大号召力。凭借深厚的客户信任和业内公认的高质量中医医疗服务及产品,公司以极具成本效益的方式吸引和留住大量客户及医疗顶尖人才。2024年,公司销售和分销开支中的推广费占总收入比例约为0.2%,远低于行业平均水平,充分彰显了品牌自带的强大引流效应。这是百年品牌壁垒最直观的量化体现,在获客成本日益攀升的医疗服务行业,这一差距意味着巨大的利润释放空间。业绩稳健增长,盈利能力持续攀升翻开同仁堂医养的财务画卷,一组组靓丽的数据勾勒出企业蓬勃发展的态势:1.收入规模持续扩大: 2022年至2024年,公司总收入从9.11亿元(人民币,下同)增长至11.75亿元,复合年增长率达13.6%。2025年前九个月,收入达8.58亿元,持续稳健增长。其中,中医医疗服务作为核心业务,贡献了总收入的84%以上,展现出稳健的主业增长动力。2.盈利能力显著增强: 2022年公司曾录得净亏损923万元,但通过高效的整合运营和精细化管理,2023年迅速扭亏为盈,实现净利润4263万元。2024年净利润进一步增至4620万元,同比增长8.4%。若剔除上市开支等一次性因素,2024年经调整净利润达6173万元,较2023年的4787万元大幅增长29%,核心业务"造血"能力持续强化。3.毛利稳步提升: 毛利从2022年的1.43亿元增至2024年的2.22亿元,复合年增长率高达24.8%,超过收入增速2倍,毛利率从2022年的15.7%提升至2024年的18.9%,盈利能力稳升,规模效应加速显现。4.现金流健康: 2024年现金转化率达87.2%,有息债务占比仅11.56%,截至2025年9月持有现金2.25亿元,资产负债表稳健。作为一家2019年版块组建的企业,同仁堂医养正处于"扭亏为盈→盈利加速"的关键拐点期。回顾固生堂的发展轨迹,2021年上市时也处于发展早期,此后三年收入和利润CAGR分别高达19%和47%,股价从IPO至今已实现数倍涨幅。同仁堂医养当前的发展阶段与固生堂上市初期高度相似--盈利能力刚进入释放通道,增长最快的阶段可能尚未到来。分级诊疗网络,三条增长曲线并行同仁堂医养并未满足于传统医疗机构的单一模式,而是前瞻性地构建起覆盖全国的分级中医医疗服务网络。截至最后实际可行日期,公司已拥有12家自有线下医疗机构及1家互联网医院,以及12家线下管理医疗机构,形成"连锁医院-基层医疗机构-互联网医院"三级联动的完整生态。这一布局产生了显著的协同效应。就诊人次飙升:医疗网络内总就诊人次从2022年的132.1万人次飙升至2024年的297.7万人次,复合年增长率高达50.1%。2025年前九个月,就诊人次已达253.6万人次,同比增长21.5%。会员粘性强劲:会员累计人数从2022年底的43.6万人增至2024年底的74.0万人,复合年增长率达30.2%,截至2025年9月底进一步增至76.7万人,显示出强大的用户粘性和品牌忠诚度。区域战略清晰:公司以北京为战略核心深入扎根,同时深耕长三角等经济活跃地区。北京地区贡献了近半数的收入,而浙江省作为公司拓展华东市场的桥头堡,2024年中医医疗服务收入达2.25亿元,毛利率达22.6%,展现出强劲的区域增长潜力。根据信息,公司的扩张主要通过战略收购、轻资产新建以及管理服务,是公司快速扩张的重要引擎。2022年,公司收购浙江"三溪堂"品牌下的医疗机构,成功切入长江三角洲地区市场。自收购以来,通过标准化管理和专业化运营整合,三溪堂保健院业绩持续提升:2022年至2024年,收入由1.025亿元增长到1.982亿元,复合年增长率39.1%;门诊人次由18.38万增至38.23万,复合年增长率约44.2%,充分验证了公司强大的投后整合能力。2024年,公司进一步收购上海承志堂等机构,强化在长三角的业务布局。此外,其另一核心扩张战略为向公立医院提供管理服务,目前已在北京、贵州、新疆、陕西等省份合作十余家医疗机构。未来募集资金也将加速这一模式的扩张布局,放大轻资产模式的利润杠杆。根据招股书披露,公司即将在齐齐哈尔和北京顺义开设自建院区,开始迈向中西医结合和高端医疗布局。名医资源汇聚,供应链精益管理中医医疗服务,医师是灵魂。同仁堂医养深谙此道,持续打造高素质的中医医师团队。截至最后实际可行日期:- 网络内共有2,745名医师加入并执业- 30名拥有国家级荣誉称号的医师,其中全国名中医2名、全国老中医药专家学术经验继承工作指导老师13名、非物质文化遗产代表性传承人5名- 拥有820名主任医师或副主任医师,占比近30%- 通过建立"名医工作室"和师承教育体系,公司已孵化13个国家级或省级名医学术传承工作室,促进宝贵中医学术理论和临床经验的代代传承- 公司还设立同仁堂中医学术咨询专家委员会,涵盖中医肾病、妇科、内分泌、肿瘤等八大医学专科,致力于中医标准化和人才培养。"炮制虽繁必不敢省人工,品味虽贵必不敢减物力"--同仁堂的古训在公司供应链管理中得到了完美诠释。公司成立全资附属公司北京通达,建立采购协同管理平台,整合网络内医疗机构的采购需求,实现规模经济,增强议价能力。在质量管控方面,公司实施严格的供应商选择标准和验收流程,定期委托第三方机构进行随机检测。2023年的一次内部盲评中,北京同仁堂中医医院所使用的中药饮片在北京多家知名中医院中得分最高,充分证明了公司在质量管理方面的卓越表现。数智化赋能百年传承,同仁堂拥抱AI浪潮公司于2020年成立同仁堂互联网医院,将传统中医诊疗与现代科技完美融合。客户可享受线上预约、健康咨询、复诊诊断、电子处方等一站式服务,打破了时空限制,让优质中医医疗资源惠及更广泛人群。截至最后实际可行日期,在互联网医院注册的医师累计提供超过84.9万次在线咨询,覆盖全国各地。公司还与超过500家外部药店建立合作关系,实现"线上诊疗+线下配送"的业务闭环,打造线上线下融合便捷服务体验。同仁堂不仅是百年工艺的传承者,更是数智化转型的排头兵,正通过与用友等战略伙伴的深度合作,将AIoT、大数据等数字技术深植于业务的每一个细胞。传统"经验主义"正被"数据主义"取代,同仁堂构建了"全链智能"的质量溯源体系,为核心产品提供了数字化护城河。2026年1月,同仁堂与北京市经信局签订任务合同书,支持开展"人工智能中药新药开发平台",构建十万级方剂数据库,通过AI技术为中药新药开发装上"智慧大脑"。同仁堂医养作为大健康终端,未来有望借助AI技术打破传统服务时空限制,通过搭建智能化健康管理平台,整合线上线下资源,为用户提供个性化的健康监测、养生指导与远程康养服务,实现从"治已病"向"治未病"的智慧化跃迁。战略蓝图清晰,估值空间可期发展阶段红利:中医医疗在港股中仍属于稀缺标的,公司当前处于盈利加速的早期阶段,随着业务进入规模化扩张期,其利润释放空间值得期待。品牌溢价尚未充分定价:三百年品牌带来的巨大流量,意味着每年节省的营销开支相当于数千万元级别的"隐形利润"。随着收入规模扩大,品牌壁垒的经济价值将进一步放大。管理服务的轻资产模式:管理服务板块从2022年至2024年收入增长700%,毛利率超70%,是高确定性的利润增长极。这条轻资产第二曲线若持续放量,将显著改善公司整体的盈利结构和ROE。集团协同的生态价值:公司是同仁堂集团"制药-零售-医养"大健康闭环的关键一环,与其他成熟版块相比,发展空间巨大,上市后将享受集团资源的持续输入。这种生态协同价值在当前估值中可能尚未被充分反映。随着3月20日招股的正式启动,同仁堂医养正以扎实的业绩、清晰的战略和广阔的前景,向全球投资者展示中国中医医疗服务行业的无限魅力。正如其名,"医"与"养"的完美融合,不仅呵护着万千民众的生命健康,更将开创中医医疗服务的新纪元。转载自格隆汇 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas ACN Newswire

From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas

SINGAPORE, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Travelling overseas is exciting, but foreign exchange (FX) fees can quietly add up and increase your overall trip expenses. Many Singaporeans are now exploring smarter ways to manage overseas spending, and a multi-currency debit card can help reduce unnecessary FX charges while shopping, dining, and booking activities abroad. Whether you are heading to Japan, Australia, Europe, or the US, understanding how FX fees work can help you stretch your Singapore dollars further. Even a 3% fee on a SGD 5,000 trip translates to SGD 150, which could easily cover a nice meal or attraction tickets.When spending overseas, banks typically apply a currency conversion spread and may also charge overseas transaction fees ranging between 2.5% and 3.5%. On top of that, dynamic currency conversion at merchants can add another 4-8% markup. These layered charges might not be obvious at checkout, but they can significantly increase your travel budget.With a bit of planning and the right payment tools, Singaporeans can minimise these costs and enjoy more transparent spending abroad.Understanding Where FX Fees Come FromBefore looking at solutions, it helps to understand how FX fees are structured. Most traditional credit and debit cards issued in Singapore apply a foreign transaction fee when you pay in a currency other than SGD. This fee usually combines the card network's conversion rate and an additional bank administrative charge.For example, if you spend the equivalent of SGD 1,000 in Bangkok or Seoul, a 3% fee adds around SGD 30 to your statement. Over a 10-day trip with shopping and dining expenses of SGD 4,000, total FX charges could reach SGD 120 or more. These amounts may seem small per transaction but can accumulate quickly across hotels, theme parks, transport passes, and shopping malls.How a Multi-Currency Debit Card Can HelpA multi-currency debit card allows users to hold and spend multiple foreign currencies directly from one account. Instead of converting SGD at the point of sale for every purchase, you can preload currencies such as USD, EUR, JPY, or AUD in advance. This setup can help reduce conversion fees and give you more control over exchange rates.For instance, if you are travelling to Japan and expect to spend the equivalent of SGD 3,000, you can convert SGD to JPY when rates are favourable before departure. If the exchange rate improves even by 1%, that difference could mean savings of around SGD 30 on your total spend.Many multi-currency debit cards also offer competitive interbank or near-interbank rates with low or zero foreign transaction fees. While terms vary by provider, this structure may result in lower overall costs compared to traditional cards. Additionally, you can track balances in different currencies via mobile apps, which helps you manage budgets more clearly during travel.Practical Ways Singaporeans Can Reduce FX ChargesBeyond choosing the right card, several practical habits can help minimise FX fees while shopping overseas.Pay in the local currency whenever possibleWhen a payment terminal offers the option to pay in SGD or the local currency, selecting the local currency can help you avoid dynamic currency conversion markups. Merchants may apply rates that are 4-8% higher than market rates when you choose SGD. On a SGD 2,000 shopping bill in Seoul, that difference could translate to an extra SGD 80 or more. Paying in the local currency often results in a more transparent rate from your bank or card provider.Plan large purchases in advanceIf you are considering buying luxury goods in Europe or electronics in Japan, estimating your total spend beforehand can help you prepare accordingly. Planning major purchases can also help you avoid last-minute conversions at less competitive airport rates.Avoid exchanging large sums at airportsAirport money changers often offer less competitive exchange rates compared to city money changers in Singapore or digital FX platforms. The difference might range from 1% to 3%. On SGD 2,000 exchanged at the airport, this gap could mean paying SGD 20 to SGD 60 more than necessary. Using a multi-currency debit card for most transactions can reduce the need to carry large amounts of cash.Monitor overseas ATM withdrawal feesWithdrawing cash overseas may involve both local ATM fees and your bank's overseas withdrawal charges. These combined costs can range between SGD 5 and SGD 15 per withdrawal, excluding FX spreads. Planning fewer, slightly larger withdrawals, or relying more on card payments, can help reduce repeated charges. Some multi-currency debit cards may offer more competitive ATM withdrawal terms, depending on the provider.Comparing Travel Spending OptionsCredit cards may offer travel rewards but often carry foreign transaction fees of around 3%. Using cash helps you to do away with card fees but requires you to exchange money upfront, sometimes at less competitive rates.A multi-currency debit card sits somewhere in between, combining digital convenience with potentially lower FX costs, while offering more flexibility. For frequent travellers visiting destinations like Malaysia, Thailand, Japan, Australia, or the US several times a year, this flexibility can make budgeting more predictable.Avoiding FX fees does not require complex strategies. Small adjustments in how you pay, when you convert currency, and which card you use can collectively reduce costs. While exchange rates fluctuate and fees vary across providers, informed decisions can help you minimise hidden charges and make the best of your overseas trips.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
中国新城镇2025年内溢利大增35.5% 持续派息回馈股东 ACN Newswire

中国新城镇2025年内溢利大增35.5% 持续派息回馈股东

香港, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 2026年3月20日,专注于中国内地投资及优质资产持有运营的中国新城镇发展有限公司("中国新城镇"或"公司",及其附属公司,统称"集团";香港股票代号:01278.HK)欣然宣布截至2025年12月31日止12个月("2025年"或"回顾期")之经营业绩。回顾期内,集团持续深化改革转型路径,在攻坚克难中交出高质量答卷。2025年集团录得主营业收入约3.89亿元(单位:人民币,下同),同比增长15%;年内溢利7571万元,同比增长35.5%;母公司权益拥有人应占溢利总额约7329万元,同比增长65.4%。董事会建议派发末期股息为每股普通股0.0025港元。主营业务稳健增长,固收业务持续优化回顾期内,集团继续保持稳健经营。2025年公司实现城镇化投资收入2.31亿元,同比增长约25%,主要因为城镇化项目投资余额较去年同期增加,对应项目投资收入增加。实现物业租赁及管理费收入人民币约1.00亿元,包括物业租赁收入人民币0.76亿元、物业管理费收入人民币0.24亿元。实现工程建设收入人民币5,717.5万元。面对国内外复杂经济形势,集团依托股东无锡交通集团与国开金融的资源优势,充分发挥"地方国资+央企金融机构"的业务网络效应,做好主营业务的管理及运营,实现了稳定增长。2025年集团城镇化投资业务稳中有进,持续贡献稳定现金流。截至2025年12月31日,固定收益投资组合总额达人民币33.66亿元。优质资产运营稳中提质。武汉光谷物业项目面对市场压力实现"止跌回升",通过精准招商与服务升级,年底平均出租率回升至75%,保证了投资性房地产估值的稳定。借力股东资源聚焦战略转型,拓展增长新空间2025年集团紧抓国家大力发展新质生产力的政策机遇,结合股东的资源优势,围绕集成电路、新能源、新材料、高端装备制造、环保等新经济方向进行优质股权项目储备,战略并购路径逐步聚焦及清晰,拟通过持有不同行业的优质资产,打造稳健收入及现金流以及后续新业务领域的增长空间。值得一提的是,集团发挥股东协同优势,在实现经营业绩稳健增长的同时,融资工作取得重大突破,成功发行15亿元离岸人民币债券,用于现有债务的再融资,进一步降低了债务成本并优化了期限结构,为集团后续业务的发展提供可持续的资金支援。持续派息,提供稳定股东回报2025年集团拟派发末期股息0.0025港币/股,加上中期已经派发的中期股息0.0016港币/股,2025年集团全年派息金额约3900万港元。自2023年中期恢复派息以来,集团累计已经派发及拟派发股息金额达到了约1.2亿元人民币,显示了持续回报股东的意愿和行动。未来展望展望2026年,作为"十五五"开局之年,集团将紧扣国家新质生产力导向,聚焦战略新兴产业与信创产业,加速业务转型。固收业务稳中提质,保障现金流;优化武汉光谷等核心资产运营,提升效能。同时,积极储备优质股权项目,力争战略并购实质突破,持续为股东创造核心价值。关于中国新城镇发展有限公司中国新城镇(香港联交所股份代号︰1278)为中国内地的投资及优质资产运营商。自2014年起,本集团顺应中国新城镇化发展趋势优化了业务模式,以"投资+下游产品运营"的业务模式,通过固定收益类项目投资作为出发点,持有优质资产管理及运营,同时以市场为导向,全力在新材料、半导体、高端装备制造等新经济领域拓展股权投资业务,积累行业投资经验。本新闻稿由千里国际顾问有限公司代表中国新城镇发展有限公司发布。如有垂询,请联络:中国新城镇发展有限公司 ir@china-newtown.com千里国际顾问有限公司Fancy Wang fancywang@maxima.hk Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
宇树科技IPO点燃具身智能行情 首程控股(0697.HK)迎来”投资兑现+平台重估”双重催化 ACN Newswire

宇树科技IPO点燃具身智能行情 首程控股(0697.HK)迎来”投资兑现+平台重估”双重催化

香港, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 人形机器人赛道再迎里程碑事件。3月20日,上交所官网显示,宇树科技股份有限公司科创板IPO申请已获受理,融资金额42.02亿元,审核状态为"已受理"。这意味着宇树科技正式向"A股人形机器人第一股"发起冲刺,也标志着具身智能产业开始从主题催化迈向资本化兑现的新阶段。从公开披露看,宇树科技此次IPO并非单纯的概念升温,而是建立在业绩高增长与产能扩张预期之上。根据公司招股说明书透露,公司2025年实现营业收入17.08亿元,同比增长335.36%;扣非后净利润超过6亿元,同比增长674.29%;公开发行新股不低于4044.64万股,占发行后总股本比例不低于10%。对资本市场而言,宇树科技最重要的意义,是开始提供一个更清晰的人形机器人估值参照系。公开报道显示,宇树科技在2025年初的估值约为50亿元,到2025年6月已提升至约120亿元;而本次招股书对应的初始发行后市值至少420亿元,意味着其公开市场估值门槛较2025年中期的一级市场口径又出现大幅跃升。对于资本市场而言,宇树科技的上市进程则是释放出一个清晰信号:人形机器人不再只是"技术想象力"的故事,而开始进入"收入、利润、产能、融资"四线并进的新阶段。对产业链而言,这将提升市场对整条赛道估值锚的清晰度;对已提前布局头部机器人的资本平台而言,则意味着账面价值、退出预期与业务协同空间都有望同步抬升。在这一轮受益标的中,首程控股(0697.HK)的稀缺性尤为突出。公司在官方披露中明确表示,已通过北京机器人产业发展投资基金及旗下产业基金,投资宇树科技、银河通用、星海图、松延动力等多家头部企业;到2025年前三季度,其管理的多支产业基金又进一步完成了对宇树科技、云深处、加速进化、微分智飞、泉智博等核心机器人产业链公司的投资,覆盖人形机器人、飞行机器人及上游关键环节。换言之,首程控股并非单点押注,而是在"头部本体企业+上游关键环节+区域基金网络"上形成了组合式布局。更关键的是,首程控股的优势不只在"投",还在"投后赋能"。公司2025年中报和三季报均提到,其正围绕"资金+场景+产业链"推进"投资+运营+生态"一体化路径,并已设立北京首程机器人科技产业有限公司、首程机器人先进材料产业有限公司,拓展销售代理、租赁、咨询、供应链管理及上游材料延伸。同时,公司在首钢园、北京首都国际机场T3、成都春熙路等场景布局常态化机器人体验店和快闪店,推动机器人产品从展示走向商业落地。对于宇树科技这类具备量产能力的明星企业而言,这种场景资源意味着更低的试错成本和更快的商业验证速度。这也是首程控股被市场视为宇树概念股的核心原因:它不是单纯二级市场"映射",而是兼具资本纽带、应用场景和产业服务能力的生态型平台。一旦宇树科技IPO顺利推进,首先受益的是首程控股机器人投资组合的市场认可度。头部项目登陆资本市场后,外部投资者会更容易对首程控股存量未上市机器人资产进行对标估值。市场人士分析,从估值逻辑上看,宇树科技IPO对首程控股至少构成三重利好。其一,首程控股的投资收益兑现预期抬升。首程控股通过北京机器人产业基金持有宇树科技3.8262%股份,位列发行前前十大股东之一。考虑新股发行稀释后,这部分旧股对应的发行后持股比例约为3.44%。按420亿元发行后市值假设测算,这一部分股权价值约为14.46亿元;若对应500亿元、600亿元上市后市值,则股权价值约分别为17.22亿元和20.66亿元,这对比首程控股的净资产体量,具有显著的边际贡献,并将对首程控股现有估值体系形成边际支撑。其二,是平台型估值中枢提升。首程控股并非传统意义上的单一财务投资者。公司主业一方面是基础设施资产业务,另一方面是以基金和产业平台切入机器人、智能制造等新赛道。机器人赛道的公开市场估值锚形成后,首程控股整个机器人投资组合有望被整体重估。其三,是机器人生态商业化提速带来的第二成长曲线。过去市场给机器人概念股估值,往往停留在"参股收益"层面;但首程控股正在尝试把机器人变成真实运营业务。公司披露已在线下体验店、机场场景、文旅园区和智能停车等多个场景推进机器人落地,并与产业方合作推动"机器人+汽车"等新业态。若宇树科技IPO后品牌效应和融资能力进一步增强,首程控股有望从"投中受益"扩展到"运营分成、渠道服务、场景服务、供应链协同"的多元受益。届时,市场看待首程控股的框架,将会从"宇树概念股"升级为"机器人生态基础设施平台"。此外,首程控股的财务结构也为估值修复提供了安全边际。公司2024年归母溢利为4.10亿港元,2024年末本公司拥有人应占股本及储备为94.21亿港元,负债资本比率从2024年末的15.9%下降至2025年三季度的10.9%。公司就2024年度合共宣派末期股息及特别派息8.88亿港元,叠加中期股息2.08亿港元,全年派息总额10.96亿港元,超出当年归母溢利的200%。较强的分红意愿、较低杠杆与持续盈利能力,使其在"成长+收益"两端都更容易获得资金青睐。总体来看,宇树科技IPO正式推上进程,是2026年具身智能产业最重要的资本事件之一。它不仅提高了头部机器人企业的资本化确定性,也为首程控股这样的生态型平台打开了价值重估窗口。随着"明星项目上市—投资收益兑现—产业场景扩容—平台估值提升"逻辑逐步展开,首程控股有望成为本轮机器人行情中兼具安全边际与弹性的核心受益者之一。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Unitree Robotics IPO Ignites Embodied-Intelligence Rally, Shoucheng Holdings (0697.HK) Faces a Dual Catalyst of ‘Investment Realisation+Platform Re-Rating’ ACN Newswire

Unitree Robotics IPO Ignites Embodied-Intelligence Rally, Shoucheng Holdings (0697.HK) Faces a Dual Catalyst of ‘Investment Realisation+Platform Re-Rating’

HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) -The humanoid robotics sector has reached another milestone. On 20 March, the Shanghai Stock Exchange confirmed that Unitree Robotics Co., Ltd. (operating entity: Hangzhou Yushu Technology Co., Ltd.) has received formal acceptance of its STAR Market IPO application, targeting proceeds of RMB 4.202 billion, with review status recorded as "Accepted". This marks Unitree Robotics' official push to become China's first A-share listed humanoid robot company, and signals that the embodied-intelligence industry is transitioning from a theme-driven narrative phase into a new stage of genuine capital-markets realisation.From publicly disclosed information, this IPO is not purely a concept re-rating event — it rests on a foundation of strong earnings growth and capacity expansion. According to the company's prospectus, Unitree Robotics generated revenue of RMB 1.708 billion in 2025, up 335.36% year-on-year; non-GAAP net profit exceeded RMB 600 million, up 674.29% year-on-year. The public offering involves a minimum of 40,446,434 new shares, representing at least 10% of the total post-IPO share count.For the capital markets, the most important contribution of Unitree Robotics is that it begins to provide a clearer public-market valuation reference for the humanoid-robotics sector. Reports indicate that Unitree's valuation stood at approximately RMB 5 billion in early 2025, rising to approximately RMB 12 billion by June 2025. The prospectus implies an initial post-IPO market capitalisation of at least RMB 42 billion — a dramatic leap from the mid-2025 private-market benchmark. For the capital markets, Unitree's listing trajectory carries a clear signal: humanoid robotics is no longer purely a story of "technological imagination" — it is entering a new phase of revenue, profit, capacity, and capital advancing on all four fronts simultaneously. For the supply chain, this raises the clarity of the sector's valuation anchor; for capital platforms that have invested early in leading robotics companies, it means book values, exit expectations, and business synergies all have room to rise in tandem.Among the beneficiary candidates in this cycle, Shoucheng Holdings Limited (HKEX: 0697.HK) stands out for its rarity value. The company has publicly confirmed that, through the Beijing Robotics Industry Development Investment Fund and its affiliated sub-funds, it has invested in Unitree Robotics, Galbot (Beijing Galaxy General Robot Co., Ltd.; X Square Robot , Noetix Robotics, and other leading enterprises. By Q3 2025, the multiple funds it manages had further completed investments in Unitree Robotics, DEEP Robotics / Hangzhou DEEP Robotics Co., Ltd.), Booster Robotics, Differential Robotics / Differential Robotics Technology Inc.), Wuxi Quanzhibo Technology Co., Ltd., and other core robotics supply-chain companies — covering humanoid robots, aerial robots, and critical upstream components. In short, Shoucheng Holdings is not a single-bet position, but a portfolio-style deployment spanning "leading robot OEMs + upstream critical components + regional fund networks."Crucially, Shoucheng Holdings' edge lies not only in "investing" but also in "post-investment value creation." Both the company's 2025 interim report and Q3 report highlight that it is advancing an integrated "Invest + Operate + Ecosystem" pathway centred on "capital + scenarios + supply chain." It has established Shoucheng Robot Technology Industry Co., Ltd. and Shoucheng Robot Advanced Materials Industry Co., Ltd., expanding into sales agency, leasing, consultancy, supply-chain management, and upstream materials. Simultaneously, the company has deployed permanent robot experience stores and pop-up stores at Shougang Park, Beijing Capital International Airport Terminal 3, and Chengdu Chunxi Road, accelerating the transition of robot products from showcase to commercial deployment. For high-volume producers like Unitree Robotics, these venue resources translate into lower trial-and-error costs and faster commercial validation cycles.This is also the core reason why the market treats Shoucheng Holdings as a premier Unitree Robotics proxy: it is not a simple secondary-market "reflection" play, but an ecosystem-type platform that combines capital linkages, application venues, and industrial service capabilities. Once Unitree Robotics' IPO advances smoothly, the first beneficiary will be the market recognition of Shoucheng Holdings' existing robotics investment portfolio. With a marquee portfolio company achieving public listing, external investors will find it far easier to mark-to-market the unlisted robotics assets still held by Shoucheng Holdings.Market analysts observe that, from a valuation standpoint, the Unitree Robotics IPO represents at least three distinct positive catalysts for Shoucheng Holdings.First, the anticipated realisation of investment returns has been significantly enhanced. Shoucheng Holdings holds 3.8262% of Unitree Robotics through the Beijing Robotics Industry Development Investment Fund, placing it among the top ten pre-IPO shareholders. After accounting for dilution from the new share issuance, the post-IPO stake corresponds to approximately 3.44%. Based on an assumed post-IPO market capitalisation of RMB 42 billion, this stake implies a value of approximately RMB 1.446 billion; at market caps of RMB 50 billion and RMB 60 billion, the implied values are approximately RMB 1.722 billion and RMB 2.066 billion respectively. Against the scale of Shoucheng Holdings' net asset base, these figures represent a material incremental contribution and will provide meaningful support to the company's existing valuation framework.Second, the platform-level valuation midpoint has scope to re-rate upward. Shoucheng Holdings is not a traditional single-strategy financial investor. Its core business encompasses infrastructure asset operations on one side, and entry into robotics and intelligent manufacturing through funds and an industrial platform on the other. Once the robotics sector has an established public-market valuation anchor, Shoucheng Holdings' entire robotics investment portfolio stands to be re-valued in aggregate.Third, the acceleration of robotics ecosystem commercialisation opens a genuine second growth curve. In the past, the market valued robotics concept stocks largely at the level of "equity participation income." But Shoucheng Holdings is actively working to transform robotics into a real operating business. The company has disclosed that it is advancing robot deployment across multiple scenarios — offline experience stores, airport environments, cultural-tourism parks, and smart car parks — and is collaborating with industry partners to develop new business formats such as "robotics + automotive." Should Unitree Robotics' brand recognition and fundraising capacity strengthen further post-IPO, Shoucheng Holdings could expand beyond "investment gains" to capture diversified value streams including operating profit-sharing, channel services, scenario services, and supply-chain coordination. At that point, the market's analytical framework for Shoucheng Holdings would graduate from "Unitree Robotics proxy" to "robotics ecosystem infrastructure platform."In addition, Shoucheng Holdings' financial structure provides a robust margin of safety for any valuation recovery. The company reported profit attributable to shareholders of HKD 410 million in 2024. Equity attributable to owners of the company stood at HKD 9.421 billion at end-2024. The gearing ratio declined from 15.9% at end-2024 to 10.9% by Q3 2025. In respect of the 2024 financial year, the company declared final dividend and special dividend totalling HKD 888 million, and together with the interim dividend of HKD 208 million, full-year distributions reached HKD 1.096 billion — exceeding 200% of the year's attributable profit. This combination of strong dividend commitment, low financial leverage, and sustained earnings power positions the stock favourably for capital flows seeking both "growth" and "income" attributes simultaneously.Taken as a whole, the formal advancement of the Unitree Robotics IPO process represents one of the most consequential capital-markets events of 2026 for the embodied-intelligence industry. It not only raises the capital-markets certainty for leading robotics companies, but also opens a valuation re-rating window for ecosystem-type platforms like Shoucheng Holdings Limited. As the logic of "flagship project listing → investment return realisation → industrial scenario expansion → platform valuation uplift" progressively unfolds, Shoucheng Holdings is well-positioned to emerge as one of the core beneficiaries of this robotics market cycle — a company that simultaneously offers a meaningful margin of safety and meaningful upside optionality. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More